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Abstract
Introduction: Sodium hemostasis is altered in patients with chronic kidney disease (CKD)
due to long term loading, and sodium (23Na) can be deposited in the skin, muscle and
skeleton. We measured 23Na content in these tissues of CKD patients, using 23Na magnetic
resonance (MR) imaging.
Methods: This is a pilot cross-sectional study of CKD stage 4-5D patients and controls with
normal kidney function. Subjects underwent a 23Na MR study of their right lower leg using a
multinuclear-capable 3.0-T MRI. An axial proton T1-weighted fast-low-angle-shot sequence
was acquired to delineate the anatomy; followed by a 23Na MR image obtained with a
custom-made 23Na coil and sodium-optimized pulse sequences. Concentration maps were
generated using saline solutions at different 23Na concentrations as calibration vials. Four
regions of interest (ROIs) were drawn: 1) pre-tibial skin, 2) posterior leg skin, 3) tibia, and 4)
soleus muscle. Baseline characteristics and blood samples were also collected.
Results: 10 controls, 12 CKD and 23 dialysis (10 peritoneal dialysis (PD) and 13
hemodialysis (HD)) subjects participated in the study. 23Na concentration in all four tissues
was significantly higher in dialysis patients compared to controls (p-value <0.05). No
significant difference was found in the tissue 23Na of HD, PD and CKD groups. Tissue
sodium levels correlated strongly with markers of mineral bone disease and inflammation.
Associated factors appear to be tissue specific.
Conclusion: Dialysis patients were found to have significantly higher 23Na level in their
tissues compared to controls with normal kidney function. The effect and clinical utility of
tissue 23Na remains to be studied.

Keywords
Sodium MRI, Non-osmotic Sodium, Tissue sodium concentration, Chronic Kidney Disease
(CKD), Dialysis, Hemodialysis, Peritoneal dialysis
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Lay Summary
Introduction: Introduction: When the kidney malfunctions, individuals cannot excrete
sodium. This results in the deposition of sodium in the skin, muscle and bones, especially in
patients who require dialysis because of minimal kidney function. We used magnetic
resonance technology to study the amount of sodium in these tissues of patients with kidney
disease.
Methods: We studied 10 healthy individuals, 12 patients with kidney disease not on dialysis
and 23 dialysis patients (13 on hemodialysis and 10 on peritoneal dialysis - the two most
common types of dialysis). Each subject was brought in for a study visit, where we collected
their medical history and blood samples, and obtained a cross-sectional image of their R leg.
The image was taken with a modified magnetic resonance scanner which detects sodium
content. We had vials with known sodium concentration included in the image, to calibrate
the level of sodium in the different regions. Four regions of interest were drawn over the
image: over the soleus muscle, the bone, and two areas of the skin (the skin over the shin and
from the back of the calf) - to highlight the different tissues.
Results: Sodium levels in all four areas (three tissues) were higher in dialysis patients
compared to healthy individuals. We did not find a difference between patients on peritoneal
dialysis, hemodialysis, or not on dialysis yet. Higher sodium levels in the muscle and bone
were associated with increased inflammation, as well as other markers of kidney disease. The
sodium levels in the different tissues were associated with different factors.
Conclusions: Dialysis patients have higher sodium levels in their skin, muscle and bone,
compared to healthy individuals. The mechanism of sodium storage and its effect on
individuals needs to be studied further.
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Chapter 1

1

Background
This chapter provides some background information about the work described in the

following chapters. This includes descriptions of the Kidney (in Health and Disease) (Section
1.1), Current Knowledge of Sodium Metabolism (Section 1.2), 1H Magnetic Resonance Imaging
(Section 1.3), and 23Na Magnetic Resonance Imaging (Section 1.4).

1.1 The Kidney – in Health and Disease
The kidney is a vital organ with several key functionalities. This section highlights the
anatomy and physiological function of the kidney, as well as definitions of CKD and renal
replacement therapies. A further in-depth description of the kidney and its role can be found in
multiple textbooks. [1-5]

1.1.1

Kidney Anatomy
The kidneys are bean shaped organs, weighting on average about 150 g each, and located

in the retroperitoneum. In total, they receive approximately 20% of the cardiac output, which is
distributed through the ~2 millions of nephrons – the functional units of the kidneys (Fig. 1-1).
[1-5] The nephron is composed of two main parts: the glomerulus and the tubules, and is
surrounded by a set of arterioles, capillaries and venules. Blood is initially filtered through the
glomerulus, producing ultra-filtrate - an acellular aqueous solution with plasma-like contents
(except for macromolecules). The contents of this ultra-filtrate are then modified by the
absorption and secretory function of the different parts of the tubule to produce the end-result:
urine.
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Figure 1-1: A) The kidney with its renal artery and vein, and ureter for urine output; B) The
nephron – the functional unit of the kidney. It has two main sections: the glomerulus and the
tubule. Adapted from [5]

1.1.2

Kidney Function

The functions of the kidney include:
-

Maintaining the body composition of water and electrolytes: The kidney regulates the
composition of the fluid in the body and its osmolytes. Using a series of feedback
mechanisms, the amount of water and other electrolytes that the kidneys excrete in the
urine are highly adaptable. As such, the kidney plays an important role in regulating the
body content of water, sodium, potassium, chloride, bicarbonate, calcium, magnesium
and phosphate. This role of the kidney is quite crucial since most cellular enzymatic
processes and electrochemical gradients rely on the tight regulation of these ionic
concentrations.

-

Excreting metabolic waste products and foreign substances: A number of end-products
and toxins are produced during physiological and pathological processes in the body,
which are cleared by the kidneys. This includes urea, creatinine, acids and drugs.
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-

Production of hormones:
o Renin: In response to renal blood flow, the kidneys will release renin – a hormone
which catalyzes the formation of Angiotensin II – a potent vasoconstrictor.
Angiotensin II not only causes significant changes in peripheral vascular
resistance, but also has direct and indirect effects in the tubular reabsorption of
sodium and water through its effect on renal vasculature and aldosterone
production by the adrenal glands. Through these mechanisms, the kidneys play a
key role in blood pressure regulation and hemodynamic stability.
o Erythropoietin: The kidney is the main site for production of erythropoietin – a
hormone that is key in stimulating the production of erythrocytes (or red blood
cells) in the bone marrow.
o 1,25-Dihydroxyvitamin D: Kidneys are needed to activate vitamin D into its
active metabolite 1,25-dihydroxyvitamin D. This active metabolite then helps
regulate body calcium and phosphate levels, as well as having feedback roles on
parathyroid hormone and bone metabolism.

1.1.3

Chronic Kidney Disease
CKD is defined by the Kidney Disease Improving Global Outcomes (KDIGO) guideline

as “abnormalities of kidney structure or function, present for >3months, with implication for
health”. [6] Even so, this condition describes a wide range of diseases that can affect the kidney
and has significant variations in severity. As such, KDIGO further classifies CKD in stages 1-5
(Table 1-1), based on the glomerular filtration rate (GFR). [6] Patients who are on dialysis are
often classified as CKD 5D, to differentiate them from CKD 5 – not on dialysis. GFR is
estimated based on serum creatinine (a molecule readily filtered in the glomerulus). [7]
The prevalence of CKD stages 1-5 is approximately 13.4% of the general population,
while stages 3-5 is 10.6%. [8] Patients with CKD are at increased risk of morbidity and mortality
– particularly cardiovascular mortality. The risk of hospitalization and cardiovascular events
progressively increases as GFR declines. [9] Survival rates for dialysis patients at one, two and
five years are approximately 81, 65, and 34%, respectively. [10] As such, due to its high
prevalence and significant disease burden, CKD is a global health concern. [11]
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Table 1-1: Description of the Stages of CKD, from mild (Stage 1) to severe (Stage 5) [6]
Stage

GFR (ml/min/1.73 m2)

Description

Stage 1

>89

Normal or high

Stage 2

60-89

Mildly decreased

Stage 3a

45-59

Mild-moderately decreased

Stage 3b

30-44

Moderate-severely decreased

Stage 4

15-29

Severely decreased

Stage 5

<15

Kidney Failure

1.1.4

Renal Replacement Therapies
When the kidney function has decreased to a level incompatible with a functional life,

patients tend to have two main options with regards to renal replacement therapies: dialysis –
either hemodialysis or peritoneal dialysis, or kidney transplantation. Furthermore, hemodialysis
is sub-categorized into in-center hemodialysis – where patients come to a medical facility three
times a week for 3-4 hours to have their treatments, or home hemodialysis – where the patients
are trained to do their own treatment in a home setting.
For the purpose of this thesis, the following sections provide information on the two renal
replacement therapies relevant to this study: in-center hemodialysis and peritoneal dialysis. More
in-depth discussion can be found in the references. [2-4,12-14]
Dialysis is a poor approximation of the kidneys – in that it helps remove particles (for e.g.
electrolytes, end products of metabolism, and drugs) and excess water from the body, but its
performance falls short of the full functionality of the kidneys. The dialysis apparatus requires
three main components: access to blood or fluid compartment in the body, a semi-permeable
membrane and dialysate fluid. Particles (or solutes) and water mostly cross the semi-permeable
membrane into the dialysate fluid (with few exceptions – e.g. bases like bicarbonate or lactate –
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which diffuse into the blood). In general, two different processes occur simultaneously during
dialysis: 1) solute clearance and 2) ultrafiltration. Solute clearance refers to the clearance of
solutes via diffusion, while ultrafiltration is the removal of fluid – via hydrostatic or osmotic
pressures. Ultrafiltration does result in some removal of solutes, since water will often drag
solutes via solvent drag across the semi-permeable membrane.

1.1.4.1

In-Center Hemodialysis

Hemodialysis is a process where blood is taken from a patient’s vessels, run through a
hemodialysis filter (Fig. 1-2) to adjust its composition, before it is returned back to the patient’s
vasculature. Inside the filter, blood runs counter-parallel to the dialysate fluid, separated through
a polymeric membrane. The counter-parallel flow is integrated to ensure maximal solute
clearance by maintaining concentration gradients throughout the filter length. Ultrafiltration rates
can be adjusted by applying negative hydrostatic pressure to the dialysate compartment of the
HD filter.
Hemodialysis Filter

Figure 1-2: Schematic representation of the hemodialysis apparatus: depicting
blood and dialysate counter current flows within the hemodialysis filter, the
membrane (in red) and the movement of solutes mostly from blood to dialysate. [13]

In-center HD is the outpatient delivery of hemodialysis treatments in hemodialysis units.
Patients come to these units usually three times a week, for 3 to 4 hour-long hemodialysis
treatments. The HD machine is set up, monitored and adjusted by trained health care
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professionals, who also closely observe the patients for complications. Since this is the only
dialysis modality that has trained professionals available for the entire treatment, in-center HD
patients tend to have lower health status and higher levels of comorbidities compared to those on
other dialysis modalities.

1.1.4.2

Peritoneal Dialysis

Peritoneal dialysis involves the transport of solutes and water across the peritoneal
membrane, which serves as the semipermeable membrane between the blood in the peritoneal
capillaries and the dialysis fluid in the peritoneal cavity. Dialysate solution is infused into the
abdomen of patients and allowed to dwell there for a set period of time (varies from 1 to over 16
hours). The transport of solutes and water between the dialysate solution and blood occurs during
this dwelling time. For solutes, this transport is dependent on concentration gradients, osmotic
and oncotic pressures (since water transports affects solute movements through convection or
solvent drag), as well as the pore sizes in the peritoneal membrane (which acts as a filter). Water
movement depends on the oncotic and osmotic pressures. Initially these pressures are set by
adding dextrose or other polymers to the dialysate fluid, but with time they adapt with the
diffusion of solutes (in and out of the peritoneal space). Overall, with longer dwell times the
concentration of solutes (like toxins, urea, phosphate etc.) in the dialysate fluid equilibrates with
that of blood. Generally, patients undergo PD for at least 8 hours, with anywhere from 1-7 dwells
a day. As such, PD prescriptions are highly adjustable.
In contrast to HD, PD tends to be less efficient with respect to solute clearances. Even so,
PD does have some advantages. First, it is less expensive than traditional in-center HD. [15-17]
Second, PD is associated with better health related quality of life. [18,19] This dialysis is done at
home by the patients or their caregivers, allowing patients the freedom, flexibility and control to
perform their own treatment regimen and facilitate their return to everyday activities. Lastly, PD
has been found to have an early survival advantage compared to in-center HD – attributed to
preserved residual renal function. [20,21]
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1.1.5

Complications of CKD
CKD results in a number of biochemical abnormalities and complications. [1-4,6,12]

These complications become more severe as CKD progresses to later stages (stage 5). Only some
of them are treated with dialysis.
o Uremia: As kidney function deteriorates, the ability of the kidney to excrete
metabolic end-products and toxins decreases. This results in an accumulation of these
compounds – including creatinine and urea (readily measured in plasma in clinical
practice) and other unmeasured non-protein nitrogen compounds. Build-up of these
toxins past a critical threshold (which is patient-specific) results in a series of nonspecific symptoms collectively known as “uremic symptoms”. Uremic symptoms
include nausea and vomiting, decrease appetite, pruritus (itch), lethargy, confusion
and decreased level of consciousness, and chest pain from uremic pericarditis. The
presence of these symptoms indicate the need to initiate renal replacement therapy,
otherwise the individual will die as a result of their kidney disease.
o Hyperkalemia: As CKD progresses, the excretion of potassium in the urine is
impaired, resulting in hyperkalemia, a dangerous condition which can result in fatal
cardiac arrhythmias. Hyperkalemia is treated with two main approaches: 1)
Decreased intake through low-potassium diet and potassium-binding resins to reduce
potassium absorption in the gastrointestinal tract; 2) Increased excretion through
diuretics (to increase excretion from the native kidneys) and renal replacement
therapies – the latter as a last resort.
o Acidosis: The kidneys ability to re-absorb and produce bicarbonate is compromised
in CKD, resulting in the build-up of acid components produced by metabolism.
Treatment of acidosis involves supplementation with sodium bicarbonate or renal
replacement therapy.
o Anemia: CKD (usually stages 4-5) often results in anemia. The mechanism through
which CKD causes anemia is multifactorial. First, as its function deteriorates, the
kidney releases less erythropoietin into the blood stream – a hormone that is needed
for erythrocyte production in the bone marrow. Second, absorption of iron (a key
element in hemoglobin) from the gastrointestinal tract is diminished in these patients.
Third, the increased toxins result in a pro-inflammatory milieu in the bone marrow –
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which diminishes its normal activity. Anemia is often treated in CKD by
supplemental iron (oral or intravenous), erythropoietin stimulating agents, and (if
needed) dialysis to increase clearance of toxins.
o Mineral Bone Disease (MBD)– As kidney function diminishes, the kidneys are
unable to re-absorb calcium, secrete phosphate and activate Vitamin D to 1,25dihydroxy-Vitamin D. These changes in calcium/phosphate homeostasis result in
secondary and eventually tertiary hyperparathyroidism (increased parathyroid
hormone- PTH), and osteomalacia and other metabolic bone diseases. Dysregulation
of the mineral bone disease markers has also been associated with increased
mortality, and vascular disease from extra-skeletal calcification in vessels. Current
treatment includes adhering to a low-phosphate diet, phosphate binders to decrease
phosphate absorption, calcimimetic agents – to trick the parathyroid gland that the
body is hypercalcemic, administration of active vitamin D compounds, and renal
replacement therapies. With regards to the latter, aside for transplantation, dialysis is
limited in phosphate removal – since the majority of this anion is intracellularly
stored, and thus, not readily accessible with dialysis.
o Water and Sodium Retention, and Blood Pressure: As CKD progresses, the residual
renal function decreases, and thus, smaller volumes of urine are excreted. These
smaller urine volumes result in less water and sodium excretion, and consequently,
increased total body fluid and total body sodium content. Clinically, this manifests as
signs and symptoms of volume overload and hypertension. Patients are advised to
decrease their sodium and water intake. In addition, attempts are made to increase
residual renal function with the use of diuretics, and once medical therapy fails, with
renal replacement therapy. Lastly, sometimes paradoxically, as CKD progresses the
kidney releases more renin, causing significant vaso-constriction and hypertension
though activation of Angiotensin II.
o Cardiovascular: CKD patients are at increased risk for cardiovascular disease and
mortality. [9, 22,23] This risk has been attributed to a higher prevalence of traditional
risk factors (e.g. hypertension, diabetes, left ventricular hypertrophy, smoking,
sedentary lifestyle, etc.), as well as non-traditional factors like chronic volume
overload, anemia, oxidative stress, and MBD. Troponin, a serological marker of
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cardiac injury, is often elevated in CKD patients – partially due to its decreased
clearance. Even so, chronically elevated troponin levels are associated with worse
prognosis in CKD. [24,25]
o Inflammation: CKD and dialysis are also associated with recurrent and chronic
inflammatory processes. [26-31] These patients often have low albumin and
hemoglobin, and high C-reactive protein (CRP) levels, indicative of inflammation.
The etiology of inflammation is believed to be multifactorial including elevated proinflammatory cytokines, oxidative stress, increased infections, and the uremic milieu.
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1.2 Current Knowledge of Sodium Metabolism
This section provides a brief overview of current teaching on sodium handling by the
body. Sodium metabolism has been previously described in multiple other sources. [1-5] The
main principle in sodium balance physiology postulates that sodium content is conserved in
steady-state:
Sodium Intake = Sodium Excretion

[1.1]

Since a large portion of the total sodium content is in aqueous solution, this section also contains
a brief explanation of the fluid compartments in the body.

1.2.1

Fluid Compartments
The total body water (TBW) is compartmentalized into intracellular fluid (ICF = ~2/3 of

TBW) and extracellular fluid (ECF = ~1/3 of TBW) (Fig. 1-3). These two compartments are
separated by the cell membrane. ECF is further divided into interstitial fluid (ISF), which bathes
all the cellular components in tissues, and plasma fluid (PF) – separated by the capillary wall.
The concentrations of the main cations and anions in the PF and ICF are highlighted in Table 12. Since these electrolytes freely permeate the capillary wall, PF concentrations are generally
assumed to be representative of ECF content. This assumption is not completely accurate, since
the protein composition (specifically albumin) of PF and interstitial fluid are different. Albumin
is negatively charged and attracts cations, thus distorting their concentration slightly in its
vicinity – a phenomenon called the Gibbs-Donnan effect. Since albumin levels are higher
intravascularly, the cation concentration is also a bit higher in the PF compartment.
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Total Body Water (TBW)
0.6 x Body Weight

Extracellular
Fluid (ECF)
0.2 x Body Weight

Intracellular Fluid (ICF)
0.4 x Body Weight

Cell Membrane
Interstitial
Fluid (IF)
2/3 x ECF

Plasma
1/3 x ECF

Capillary Wall

Figure 1-3: Estimates of major body fluid compartments with respect to body weight and
the membranes that separate these compartments. Adapted from [5]

Table 1-2: Typical ionic composition of plasm and intracellular fluid (adapted from [1,4])
Constituent

Blood Plasma (mmol/L)

Intracellular fluid (mmol/L)

Sodium (Na+)

143

12

Potassium (K+)

4

150

Chloride (Cl-)

104

4

Bicarbonate (HCO3-)

24

10

1.2.2

Sodium Intake
In industrialized countries, average sodium intake is 100-200 mmol/day (~2-4 grams/day)

[29,30]. Since humans can survive and function normally on 10-20 mmol/day, current sodium
intake is almost always greater than the amount necessary for homeostasis. Yet, salt appetite is
often independent of salt-repletion. However, sodium-deplete states – often perceived as
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decreased blood volume, low blood pressure, or decreased extracellular fluid sodium
concentration – are significant stimuli for both sodium appetite and water thirst.

1.2.3

Sodium Excretion
The sodium balance equation [1.1] translates a precisely balanced sodium and water

intake with their excretion, in order to keep the size of the ECF constant. Sodium loss is
dependent on three main mechanisms: losses through sweat and the gastrointestinal tract – which
are not regulated, and renal losses which are. Sodium excretion by the kidney is subject to 1)
ultrafiltration in the glomerulus, and 2) reabsorption in the tubule. Sodium is not secreted in
urine. Since sweat and gastrointestinal losses are minimal (less than 5mmol/day and
approximately 10mmol/day, respectively) in regular conditions (room air, regular activity and
normal bowel movements), [32] the following explanation on the regulatory mechanism of
sodium excretion is focused on renal losses.
Since sodium is the most abundant extracellular cation, it is a key osmolyte regulating the
ECF volume, and thus, effective circulatory volume (through PF) and blood pressure. As such,
any fluctuations in total body sodium results in concurrent fluctuations in ECF volume. In
response, a number of regulatory feedback mechanisms are activated (Fig. 1-4, described in
multiple textbooks [1-5]):
-

Sympathetic Nervous System (SNS): fluctuations in the ECF volume are readily detected
by stretch and baro-receptors in the blood vessels. If ECF volume is low, these receptors
will activate the sympathetic nervous system. Increased sympathetic activity increases
renal arteriole vasoconstriction – decreasing GFR and ultrafiltration, and enhances renal
salt reabsorption in the tubule.

-

Renin-Angiotensin-Aldosterone System: Renin release by the kidneys is triggered by low
intravascular fluid volumes (detected as decreased tubular flows), baroreceptor
stimulation and direct adrenergic activity (sympathetic nervous system). Renin catalyzes
the activation of Angiotensin II, a potent vasoconstrictor. Similar to the sympathetic
activity, Angiotensin II decreases sodium excretion by affecting both ultrafiltration (by
decreasing GFR) and directly enhancing sodium reabsorption in the proximal tubule. In
addition, Angiotensin II stimulates the production and release of aldosterone from the
adrenal glands. Aldosterone, in turn, acts at the collecting tubule (the most distal part of
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the nephron) to increase the activity of epithelial sodium channel, ENaC, to reabsorb
more sodium and excrete potassium.
-

Urodilatin, Uroguanylin/guanylin, Atrial Natriuretic Peptide (ANP) and Brain Natriuretic
Peptide (BNP): Multiple organs have their own hormone peptides to help adjust sodium
(and subsequently water) content in the body. ANP and BNP are peptides produced by
atrial and ventricular myocytes, respectively, in conditions of increased cardiac stretching
– or volume expansion. Urodilatin is produced by the kidneys, and uroguanylin/guanylin
are produced by the gastrointestinal tract in response to oral ingestion of sodium. All
these peptides induce natriuresis (or excretion of sodium) along the nephron tubule.

-

Increased Cardiac Output: Increased cardiac output results in vasodilation of the renal
arterioles, increasing GFR and thus ultrafiltration and ultimately loss of sodium.

-

Tubulo-glomerular Feedback: Changes in the GFR can be induced in the kidney by local
feedback mechanism from the flow rate and content of ultrafiltrate in the tubules. These
ultrafiltrate factors result in changes in the Starling forces via hydrostatic and oncotic
pressures that are detected by the tubules. Changes in these factors initiate a negative
feedback that serves to restore normal Starling forces in the tubule.

-

Water Reabsorption and Antidiuretic Hormone (ADH): Since sodium and water balances
are quite closely interconnected, water reabsorption in the kidneys also plays a role.
Water reabsorption is mostly controlled by osmoreceptors in the brain which detect
changes in plasma osmolality. When this osmolality is increased, ADH is produced, a
hormone that stimulates free water absorption in the kidney. Furthermore, ADH is
stimulated by decreased circulatory volume, with the aim of restoring it. Thus, ADH
indirectly affects sodium metabolism, by its effect on the circulatory volume.

Through these mechanisms, sodium excretion by the kidney can fluctuate from virtually zero, to
several hundreds of millimoles per day [33]
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Decreased Effective Circulating Volume

Renal Receptors

Renal Responses:
1. Tubuloglomerular
feedback
2. Renin,
Angiotensin,
Aldosterone
system

Vascular and CNS
Receptors

Brain Responses:
1. Sympathetic
nervous system
2. Pituitary/ADH

Cardiac Receptors

Cardiac Response:
1. ANP
2. Cardiac Output

Altered Renal Tubule Transport and Hemodynamics

Decreased Sodium Excretion

Figure 1-4: Key players in regulating effective circulating volume and sodium excretion by
the kidneys. CNS- Central nervous system, ADH – anti-diuretic hormone, ANP – Atrial
natriuretic peptide. Adapted from [34]

1.2.4

Sodium in Disease
A high salt diet has been implicated in a number of diseases including hypertension,

glucose intolerance, cardiovascular disease, progression of CKD, autoimmune conditions and
even cancer. [34-43] Such diets also interfere with treatments – for example high salt diets make
anti-hypertensive drugs less effective, and trigger episodes of congestive heart failure (CHF).
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Given that sodium excretion is mostly a renal process, it is believed that dysregulation in the
kidney function contributes to sodium retention and consequently disease. More specifically, in
hypertension, the kidney is believed to have an inherent inclination toward sodium and water
retention, which reset the pressure natriuresis (i.e. higher blood pressures are needed to excrete
the steady state sodium intake).
In CKD and dialysis patients, sodium excretion is impaired. 24-hour urine collections of
CKD patients show decreasing sodium excretion with advancing CKD. [43] This is particularly
important for dialysis patients, who often have negligible urine outputs. As such, these patients
are at increased risk of sodium loading – especially in between their dialysis sessions (usually
hours for PD, and up to 3 days for HD). Dialysis does remove sodium, yet sodium removal
patterns are hardly physiological due to their intermittent pattern, especially for hemodialysis
(due to its short intra-dialytic and long inter-dialytic times). [42-44] Thus, this population may be
quite vulnerable to salt-related pathophysiological changes.

1.2.5

Sodium in CKD
CKD is comprised of a large group of heterogeneous pathophysiological conditions. As

such, depending on the exact mechanism and severity, the effect on sodium hemostasis can be
variable. The mechanism of CKD progression and its effect on sodium balance has been
discussed in detail in previous literature. [1-5,12] This section provides a brief summary.
Patients with CKD can experience both sodium retention and sodium depletion. The
latter is less common and often a consequence of tubulo-interstitial disorders (affecting the
tubules and interstitial space). In these conditions, the tubule loses its ability to re-absorb sodium,
which results in high sodium losses in the urine. Glomerular diseases are more common and
result in increased sodium retention.
If a critical number of nephrons is damaged, the remaining nephrons will be exposed to
increased blood flow and compensate by hypertrophying and increasing their GFR. While these
adaptive changes are beneficial in the short term, in the long term they result in glomerular injury
and increase proteinuria (leaking of protein into the urine). Furthermore, increased Angiotensin
II local cytokine activity cause inflammation and fibrosis of the glomerulus and the vessels.
Glomerular scarring decreases the ultrafiltration in the glomeruli, while Angiotensin II increases
sodium reabsorption (as explained above), thus increasing sodium retention.
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In CKD, in order to try to maintain a neutral sodium balance, patients are often
prescribed low salt diets (less than 2g of sodium a day) and diuretics. These medications work by
decreasing sodium re-absorption in different parts of the tubule, and thus increasing the sodium
loss from the functioning nephrons.

1.2.5.1

Sodium in Dialysis

Sodium excretion in dialysis patients consist of the cumulative losses from dialysis and
residual renal function (equation [1.2]). These patients often have minimal residual renal
function, and thus need to rely on the clearance and ultrafiltration processes of dialysis to excrete
most of their sodium intake (equation [1.3]). Sodium handling during dialysis has been
previously outlined in the literature [12,34,46,47]

Sodium Losses = Renal Sodium Excretion + Dialysis Sodium Removal

[1.2]

Dialysis Sodium Removal = Diffusive Removal + Ultrafiltration Removal

[1.3]

For in-center HD, sodium removal is dependent primary on ultrafiltration through
convective losses (~78%), rather than clearance through diffusive losses (~22%). [48] As fluid is
pulled from the body, it drags with it sodium – a phenomenon called “solvent drag”. The sodium
concentration in the ultrafiltrate is slightly lower than that of plasma due to the Gibbs-Donnan
effect of proteins (i.e. the effect of the negatively charged proteins on this positive cation, as
explained in Section 1.2.1). Thus, sodium removal with ultrafiltration depends primarily on the
amount of fluid removal (i.e. if HD removes 2L of fluid with a plasma concentration of
140mmol/L, this results in a bit less than 280mmol of sodium removal with ultrafiltration).
Diffusive losses of sodium serve to fine tune the sodium balance in these patients. Yet, not all
plasma sodium is available for diffusion. The easily diffusible sodium is dissolved in the aqueous
component of plasma, unbound to other molecules. The diffusion process is dependent on the
concentration gradient between plasma sodium and dialysate sodium. This latter parameter can
be adjusted in the HD machine (in the range of 132-155mmol/L) for each patient. Thus, diffusive
losses are variable and depend on the difference between the set dialysate sodium concentration
and the pre-HD plasma sodium levels for each specific patient. [49]
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Since the 1980s, dialysis units adopted a higher sodium concentration in the dialysate,
since it reduces intra-dialytic hypotension and increases patient tolerance of the HD process. [50]
This often results in dialysate sodium concentration which are higher than plasma sodium ones;
and thus, a diffusive influx of sodium into the body. In general, post HD plasma sodium exceeds
pre-HD levels by 2-4mmol/L – implying that total losses during dialysis are hyponatremic.(i.e.
the concentration of sodium in the fluid losses during dialysis is lower than that of plasma) [50]
Unfortunately, this approach can result in lower sodium removal compared to intake, and thus
sodium accumulation in the body. Higher dialysate sodium is associated with increased interdialytic weight gains and higher blood pressures in patients. [51] In addition, while sodium
removal in HD can be increased by rising ultrafiltration rates, there are clinical limitations to the
amount of fluid removed due to patient symptoms. Furthermore, increased ultrafiltration rates are
associated with hemodynamic disequilibrium and organ dysfunction. [52-58]
Equations [1.2] and [1.3] also apply to peritoneal dialysis. In contrast, the dialysate
sodium concentration in PD is usually set at 132mmol/L (dialysate fluid bags used in North
America come pre-packaged at this concentration). When dialysate is infused into the abdomen,
the high osmolality from its carbohydrate content causes an influx of water. This water influx
drags along some sodium cations through solvent drag. This ultrafiltrate fluid has slightly lower
sodium concentration than plasma (due to the Gibbs-Donnan effect) and results in an initial
decrease in the sodium concentration in the peritoneal fluid. [59] While the sodium concentration
is lower, total sodium content is higher due to the increased volume of fluid. As the fluid is left
to dwell in the peritoneal space, the sodium concentration rises toward plasma sodium levels due
to diffusion. Yet, the osmotic gradient is usually slowly lost when the dialysate contains simple
carbohydrates which are easily absorbed. The loss of the osmotic gradient decreases the dialysate
volume. As such, depending on the initial osmotic gradient, dwell time and the rate of osmotic
gradient loss (dependent on the properties of the peritoneal membrane), the amount of sodium
and fluid removal is variable. In order to adjust sodium and fluid removal several parameters can
be adjusted: the initial osmotic gradient, dwell time and number of cycles. Even so, increasing
osmotic gradient by adding more carbohydrate results in significant metabolic consequences
(e.g. insulin resistance) and damage to the peritoneal membrane. Lastly, dialysis solutions exist
containing complex carbohydrates which are not readily absorbed, and thus maintain osmotic
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and oncotic pressures, but these solutions have only been studied as single dwell solutions over
24 hours (i.e. they are only used for one dwell a day).
The majority of sodium removal in PD, similar to HD, occurs due to ultrafiltration
(removal of sodium from fluid removal), as opposed to diffusion. [60] Attempts have been made
to increase sodium removal via lowering dialysate sodium concentration in this modality to
increase sodium removal with mixed results. [61-64]
Thus, both dialysis modalities remove sodium mostly through ultrafiltration, with some
contribution from diffusion. Different parameters can be adapted to increase sodium removal, but
these are limited due to hemodynamic and metabolic consequences.
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1.3

1

H Magnetic Resonance Imaging

This section provides general information about the principles of magnetic resonance
imaging (MRI). Further details about this technology can be found in several references. [65-68]
MRI is an imaging modality that utilizes the magnetic properties of nuclei to develop
images of tissues and structures. This technology is used extensively in the medical field to form
3-dimensional images of the anatomy and the physiological processes of the body with unparalleled soft tissue contrast. Furthermore, it can detect pathological changes in tissues and thus,
help diagnose medical conditions.
In this modality, patients are placed in a strong homogenous magnetic field (1.5-3.0 T in
clinical systems) generated by superconducting magnets. The temperature of these magnets is
maintained near absolute zero (4.2 K) by liquid helium to eliminate electrical resistance in their
windings. This sustains a large persistent electrical current in the magnet and a commensurate
magnetic field within the MRI system.

1.3.1

Nuclear Spin and the Effect of External Magnetic Fields
In principle, any nucleus with an odd number of protons or neutrons can be detected with

magnetic resonance. Biologically relevant nuclei include 1H, 13C, 15N, 17O, 19F, 23Na and 31P.
Compared with other imaging modalities MRI has an intrinsically limited sensitivity and in-vivo
MRI is typically restricted to 1H imaging due to its high tissue concentration and high sensitivity
for MR. Protons (1H) have a nuclear spin, I = ½. The strength of their interaction with magnetic
fields is determined by their magnetic dipole moment, 𝜇 given by
𝜇 = 𝛾𝐼

[1.4]

where 𝛾 is known as the gyromagnetic ratio. The signal in MRI scales as 𝛾 3 and the
gyromagnetic ratio for protons is 42.576 MHz/T, which is the largest value for any nucleus.
When water-associated protons in tissue are placed in a magnetic field, 𝐵0 , their magnetic dipole
moments precess around the magnetic field direction (Fig. 1-5) at the Larmor frequency, 𝜔0
given by:
𝜔0 = 𝛾𝐵0 .

[1.5]
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Under normal conditions at body temperature there is a small preference for the cone of
precession to be oriented in the direction of the magnetic field. This leads to a net magnetization,
⃗⃗⃗⃗⃗0 ) of the protons and hence the tissue. The amount of magnetization, M0 is dependent on the
(𝑀
concentration and magnetic dipole moment of the protons as well as the temperature of the
sample (body temperature for tissue).

A

B
B0

Parallel

Anti-parallel

B0

Figure 1-5: Dipoles in an external magnetic field B0: A) Alignment of the dipoles with the
magnetic field in the parallel or anti-parallel directions, and B) Processing of the dipole at
Larmor frequency around the axis of the external magnetic field B0. Adapted from [65]
MRI imaging works by perturbing the direction of the ⃗⃗⃗⃗⃗
𝑀0 vector away from ⃗⃗⃗⃗
𝐵0 by
applying a brief radiofrequency (RF) pulse (creating a time-varying ⃗⃗⃗⃗
𝐵1 magnetic field at the
Larmor frequency in a direction perpendicular to ⃗⃗⃗⃗
𝐵0). The magnitude of ⃗⃗⃗⃗
𝐵1 is much weaker than
⃗⃗ 𝑡 , which precesses
that of ⃗⃗⃗⃗
𝐵0, on the order of 50 T. This produces a transverse magnetization, 𝑀
around the magnetic field, ⃗⃗⃗⃗
𝐵0, (whose direction is conventionally assumed to be along the z-axis)
⃗⃗ 𝑡
in the xy plane at the Larmor frequency. This is depicted in Fig. 1-6. The initial amplitude of 𝑀
is determined by the duration and amplitude of the RF pulse quantified by a quantity known as
the flip angle, , which can range from a few to 90 degrees. After the RF pulse is turned off, the
⃗⃗ 𝑡 decays as the z-component of the longitudinal
amplitude of the transverse magnetization, 𝑀
magnetization, 𝑀𝑧 regrows. This asymptotic regrowth of the longitudinal magnetization is
known as spin-lattice relaxation, which is governed by the spin-lattice relaxation time constant T1
as described by equation [1.6]:
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𝑀𝑧 (𝑡) = 𝑀0 (1 − 𝑒

−𝑡⁄
𝑇1 )

[1.6]

T1 is known as the spin-lattice relaxation time because it is indicative of the time needed
for the nuclei to lose the energy absorbed from the RF pulse into the surrounding lattice to
produce longitudinal relaxation. T1 is dependent on tissue type, temperature and magnetic field
strength.

B0

Mz
𝛼

y
Mt

x
Figure 1-6: The initial effect of the RF pulse B1 on the magnetization vector of the tissues
M0. Initially M0 is flipped from the z-axis, with a flip angle , and has two components:
longitudinal component (Mz) and transverse component (Mt). Adapted from [66]
Prior to the RF pulse, the magnitude of the transverse magnetization, Mt is zero, and after
the pulse, its magnitude exponentially decays back to zero, via the following equation:

𝑀𝑡 (𝑡) = 𝑀0 𝑒

−𝑡⁄
𝑇2 .

[1.7]
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T2 is the transverse relaxation time (also known as the spin-spin relaxation time) and is due to
dephasing of individual nuclear spins while precessing in the xy plane. This dephasing is a result
of the interactions of the spins with each other. In practice, the effective relaxation time (𝑇2∗ ) is
actually shorter than that predicted by natural atomic and molecular mechanisms due to external
field inhomogeneities The external magnetic field ⃗⃗⃗⃗
𝐵0 produced by the superconducting magnet
is not strictly uniform, and even though shim coils are employed to increase uniformity, small
inhomogeneities still exist (usually more significant the farthest from the central bore of the
magnet). In addition, certain tissues induce magnetic changes – depending on their magnetic
susceptibility and add to these imperfections. T2 decay tends to be 5-10 times faster than T1
recovery for any given tissue type.

1.3.2

MRI Signal Detection
After excitation of the longitudinal magnetization, the resulting transverse magnetization

will induce a sinusoidal voltage in an RF receive coil, which is the source of the MR signal. This
signal needs to be significantly larger than any random or spurious fluctuations known as noise
for good imaging. Signal-to-noise (SNR) levels in MRI imaging depend on the magnitude of the
⃗⃗⃗⃗⃗
𝑀0 , which in clinical medicine – at body temperature, tends to be relatively small. Since M0 also
depends on nuclear density, water protons in tissue are the best option for in-vivo imaging since
they have the highest concentration (~88 mol/L). M0 also increases with the magnitude of the
external magnetic field B0 (for e.g. from 1.5 to 3 T).
For effective excitation and detection of the transverse magnetization, the RF coils are
resonant antennas tuned to the Larmor frequency of a specific nucleus such as protons. Often a
separate larger tuned transmit RF coil is used for uniform excitation of the protons and a smaller
receive coil or array of coils are employed as close as possible to the region-of-interest for
maximum signal reception since the receive signal decreases rapidly with distance.

1.3.3

Pulse Sequences
In order to acquire MR images, the excitation of the longitudinal magnetization and

detection of the resulting transverse magnetization needs to be repeated multiple times. The set
of instructions defining RF excitation, gradient fields for signal location and signal reception is
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called a pulse sequence. Key pulse sequence parameters, which control the acquisition of MR
images include:
1) Time-to-repetition (TR) or “repetition time”, which governs how often the pulse
sequence is repeated;
2) Time-to-echo (TE) or “echo time”, which determines the time interval between signal
measurements within a single TR;
3) Flip angle (), which determines how much of the longitudinal magnetization is
“tipped” into the transverse (xy) plane
4) Number of excitations (NEX), which specifies the number of signal averages to
improve SNR.
These pulse sequence parameters are specified by the operator to obtain MR images with specific
information and SNR.
Since the transverse magnetization (Mt) decays quicker than the recovery of the
longitudinal magnetization (Mz) after the application of the initial RF pulse, several techniques
are used to reverse this decay and create an “echo” signal. Two common techniques are used in
spin-echo and gradient-echo sequences. In spin-echo sequences, the dephasing of the spin is
refocused by applying a 180˚ RF pulse (a certain time after the initial 90˚ pulse). This refocusing
of the spins also reverses the effects of field inhomogeneities. On the other hand, in gradientecho sequences, the flip angle () is chosen to be less than 90˚, to ensure the longitudinal
component (Mz) has an adequate magnitude, and a gradient magnetic pulse is utilized to refocus
the dephasing (Fig. 1-7). Typically, with gradient-echo sequences, slice images are acquired one
slice at a time.
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RF(t)

Figure 1-7: Gradient-echo sequence – showing the exciting RF pulses, the gradient (G(t))
magnetic field applied and the signal detected (initial and the echo formed by G(t)) over
time. Adapted from [66]

1.3.4

Proton Density, T1 and T2 Imaging
Images in MRI can be T1-weighted, T2 (or T2*)-weighted or proton density weighted,

where the contrast between different tissues are enhanced based on their intrinsic T1, T2 and
proton densities, respectively. Depending on the pulse sequence utilized, TE and TR (and even
the flip angle) can be optimized to get any of the three types of images. Tables 1-3 and 1-4
demonstrate the type of images obtained for standard spin-echo and gradient-echo sequences at
different parameters.

Short TE

Long TE

Short TR

T1- weighted

mixed

Long TR

Proton-density weighted

T2 weighted

Table 1-3: Type of Images obtained depending with 1H MRI depending on TE and TR with
spin-echo sequences
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Small

Large

Flip Angle (𝜽)

Proton-density weighted

T1-weighted

TR

T2*-weighted

T1-weighted

TE

Proton-density weighted

T2*-weighted

Table 1-4: Type of images obtained with 1H MRI depending on the flip angle, TE and TR
with gradient-echo sequences

Note, that for spin-echo sequences T2-weighted images can be obtained since field
inhomogeneities have been removed, while for gradient-echo sequences only T2*-weighting can
be obtained. In general, solid tissues with rigid lattices have increased spin-spin interactions and
thus shorter T2, while in water these interactions are less, resulting in longer T2 values. As such,
in T2-weighted images fluids tend to be bright due to their higher transverse signal.
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1.4

23

Na Magnetic Resonance Imaging

MRI requires a non-zero magnetic dipole moment to detect a nucleus. While current
clinical MRI focuses on detecting hydrogen (due to its abundance in tissues and large
gyromagnetic ratio), this technology can be adapted to detect other nuclei. In biological tissues,
sodium yields the strongest MR signal after 1H. [69] The detection of sodium is possible since
23

Na nuclei possess a nuclear spin of 3/2. 23Na MRI has been utilized since the 1980s [70-76];

even so, this technology does have significant challenges and limitations.

1.4.1

Technical Adaptation for 23Na MRI
Since 23Na has different nuclear properties compared to 1H (Table 1-5), 23Na MRI

requires specific technical adaptation – in terms of both RF hardware and pulse sequences.
Custom RF coils are needed for the excitation and detection of the 23Na nuclei at their specific
Larmour frequency. [77] These RF coils are highly optimized and can be paired with short echo
times in pulse sequences to maximize possible SNR. Furthermore, these RF coils should not
interfere with proton imaging, which are also needed for anatomical context. Lastly, since 23Na
has specific excitation and relaxation properties, the pulse sequences used also need to be
adapted (in terms of TR, TE and flip angle).

Spin Quantum Number

Gyromagnetic Ratio (MHz/T)

1H

1/2

42.6

23Na

3/2

11.3

Table 1-5: Difference between hydrogen and sodium nuclei in terms of their spin quantum
number and gyromagnetic ratio. [66]
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1.4.2

Limitations and Challenges with 23Na MRI
The main challenge with 23Na MRI is that relative to 1H, 23Na concentration in tissues is

much lower. As shown in Table 1-2, 23Na concentration in the ICF and ECF is 143 and 12
mmol/L, respectively. These values are approximately 1000 times smaller than the hydrogen
concentration (~80mol/L), limiting the signal that can be acquired within a reasonable amount of
time. In addition, since the signal for MRI scales as 𝛾 3 , the lower gyromagnetic ratio for 23Na
also contributes to lower SNR.
Furthermore, due to its 3/2 spin, 23Na exhibits a quadrupolar moment. This additional
moment results in bi-exponential T2 relaxation with a short and a fast T2 component, which is
dependent on the molecular environment. The short component generally contributes ~60% of
the signal, while the long one corresponds to the remaining ~40% [78]. In order for both
components to be detected, ultrashort TE (less than 0.5ms) and short T1 are required. [78]

1.4.3

Quantifying Sodium Concentration with 23Na MRI
In order to quantify absolute in-vivo sodium concentrations with MRI, the sensitivity

profile of the RF system needs to be measured. This is typically undertaken in a separate
experiment using an imaging phantom containing a uniform known concentration of sodium
such as saline solution. Sodium MRI images are acquired for these phantoms, which are assessed
for regional variation in signal. These relative signal maps are then used to normalize in-vivo
sodium images. [79] In addition, for in-vivo 23Na MRI studies, three or four calibration vials with
known sodium concentrations (spanning the expected range of sodium concentrations to be
observed) are incorporated within the field of view of the receiving RF coil. Linear trend analysis
is then used to quantify the tissue sodium concentration in the voxel of interest.
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Chapter 2

2

Non-Osmotic Sodium: What do we know? (A review)
This chapter provides a review of the current knowledge of non-osmotic sodium: the

rationale behind this hypothesis (Section 2.1), our current knowledge (Section 2.2), and its
clinical significance (Section 2.3).

2.1 Rationale behind Non-Osmotic Sodium Hypothesis
Sodium is a key element that plays important biological roles in several physiological
processes in the human body. While it is known that significant amounts of sodium are stored in
the matrix of osseous tissue, mixed connective tissue and cartilage, [1-5] this stored sodium has
been assumed to be relatively biologically quiescent and impervious to short term fluctuations in
sodium intake and excretion. The biologically active sodium is believed to be the osmotically
active one (O-Na), found primarily in the extracellular fluid compartment. This O-Na is thought
to be strictly regulated primarily by the neurological osmostat and baroreceptors, and the
kidneys. Furthermore, due to its aqueous state, it is assumed to be directly proportional to water
balance. [6,7] For the purpose of this review, we refer to the sodium stored in tissues without a
corresponding increase in water as non-osmotically active sodium (NO-Na). At steady state,
humans are believed to have net neutral sodium and water balances [7]; thus, implying that
sodium does not move freely between the osmotically active and non-osmotically active
compartments. In fact, the NO-Na has largely been ignored in clinical medicine; for example, it
is omitted from consideration in the treatment of patients with dysnatremias. [8-10] The
corrective equations are based on water equilibrium and active osmolytes such as sodium and
potassium. [8-10]
Yet, follow up studies evaluating the accuracy of these equations and models have shown
significant disparities between the expected and observed sodium corrections [10-15]. In a short
term experiment, Engberink et al. [11] studied the effect of infusing 5mmol of sodium per L of
total body water over 30min in 12 healthy individuals during the first four hours post infusion.
They found that these models overestimated the change in plasma sodium - even when
accounting for urinary sodium losses. In an observational study, Hessels et al. [13]
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retrospectically assessed sodium balance in 38 critically ill patients during their first four days in
an ICU setting, and found that while the plasma sodium did not change significantly, patients
had a positive sodium balance of 1441±75 mmol (unaccounted by weight changes). A second
observational study in the ICU setting found that the development of hypernatremia could not be
explained by sodium and water balances. [14]
Heer et al. [12] performed a meticulously controlled, randomized study in 32 healthy
males in a metabolic ward, where subjects were given diets with a set of different sodium
quantities for at least 7 consecutive days. Sodium and water balances were calculated based on
intake and excretion from the kidneys, gastrointestinal tract, sweat and insensible losses. Body
fluid compartments were analyzed using inulin-dilution methods, mean corpuscular volume of
erythrocytes and red cell mass. This group found that while higher sodium diets did result in
larger plasma volumes, there was no significant change in the extracellular volume, intracellular
volume or total body mass - despite positive sodium balances.
Lastly, in a set of controlled simulated space-flight experiments lasting anywhere form
105 to 205 days, [16-18] the sodium balance of healthy men was evaluated during longer periods
of time. These experiments revealed that sodium accumulation was unrelated to changes in body
weight (and thus extracellular compartment) and that in humans, regulation of sodium and water
is not circadian. [16-18]
A recent systematic meta-analysis of the current literature found that only 93% of the
ingested sodium is accounted for in 24-hour urine collections; and when looking at studies in
controlled environments, this amount dropped to 84%. [19]
All these studies suggest an uncoupling of sodium and water homeostasis that could only
be explained via a more fluid equilibrium between the osmotically active and non-osmotically
active sodium storage compartments. This review focuses on our current knowledge of this nonosmotically active sodium buffering system and its biological implications.

2.2 Current Knowledge of Non-Osmotic Sodium
A more fluid equilibrium between the O-Na and NO-Na stores has been hypothesized for
more than 50 years. One of the first studies to notice an exchangeable reservoir of sodium in
healthy individuals was completed in the 1960s. [20] In their study, Streeten et al. administered
radiosodium to 7 normal young men and noticed sodium exchange with an enlarging pool for up
34

to 28 days – suggesting that the two sodium reservoirs equilibrate over time. [20] With the
development of new technological advances, our current knowledge of this non-osmotic sodium
buffering system has increased significantly.

2.2.1

Measuring Techniques
Several methodologies have been applied to quantify NO-Na stores. Initial studies [1-4]

analyzed cadaveric human and animal bones by chemical and caloric removal of adherent
tissues, water and fat. The left-over tissues were dissolved by HNO2 digestion in platinum
crucibles and sodium content was determined with a lithium internal standard Barclay flame
photometer. [21] Furthermore, several early studies utilized radio-active 22NaCl to analyze invitro, [22] ex-vivo [3, 23] and in-vivo [20] sodium content of tissues. In these experiments, 23Na
in the tissues was allowed to equilibrate with known concentrations of its radio-isotope 22Na, and
radioactivity levels were measured to quantify sodium levels. In addition, in 1988 Warner et al.
utilized electron probe analysis and analytical electron microscopy to detect ex-vivo sodium
content in the layers of human skin. [24]
More recently, in several ex-vivo studies, sodium content of tissues from animal or
human sources was determined using ashing. [25-30] With this technique, tissues are initially
desiccated and ashed, before sodium atomic levels could be measured with flame photometry
[25,26] or atomic absorption spectrometry [27-30]. Alternatively, frozen tissue sections have
been analyzed with inductively coupled plasma-optical emission spectrometry. [31]
While the above methodologies are relatively accurate, they tend to be cumbersome
(partly due to their invasive nature) and unsuited for repeat sampling attempts or in-vivo clinical
settings. [26] Even the previous in-vivo assessments done by Streeten et al. [20] are limited due
to radiation exposure. These limitations were eliminated with the advent of 23Na MRI. Since
sodium is an ion with an odd atomic number – it is detectable by magnetic resonance detection
and imaging. This relatively novel technology was first utilized in the 1980s and 1990s to image
normal and ischemic canine and rabbit hearts. [32-34] Even so, Kopp at al. were the first to
utilize 23Na MRI in assessing NO-Na content of tissues. [26] The accuracy of sodium
quantification with 23Na MRI has been previously validated against ashing techniques in both
animal and human studies. [26, 34, 35] In addition, Dyke et al. recently assessed its reliability in
skin and muscle tissues of healthy individuals. [36] Thus, 23Na MRI technology allowed for in-
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vivo, accurate, non-invasive measurements of sodium content in tissues of human beings,
suitable for repetitive and dynamic quantification.

2.2.2

Mechanism Non-Osmotic Sodium Storage
Two main mechanisms for NO-Na storage in tissues have been proposed – with variable

levels of supporting evidence: glycosaminoglycan (GAG)-bound and intracellularly-stored.

2.2.2.1

Glycosaminoglycan-Bound Sodium

One of the key components of the extracellular matrix are proteoglycans. These
molecules consist of a core protein with one or more covalently-bonded long unbranched
polymer of disaccharide units, or glycosaminoglycan. GAGs can be sulfated, affecting their
negative charge density. [37] This negatively charged GAGs are believed to recruit sodium
atoms and render them non-osmotically active. [38,39]
The association between increased tissue sodium and GAGs was first noticed by Ivanova
et al. in the 1970s. [5] This Russian group demonstrated that in Wistar albino rats fed different
sodium content, increased storage of sodium in the skin correlated with an increase in negatively
charged sulfated GAGs. Similarly, in a series of experiments in Sprague-Dawley rats, higher skin
NO-Na was associated with higher GAG content in skin, while sodium deprivation correlated
with reduced sulfated GAGs and increased hyaluronan (non-sulfated GAG). [39,40] Direct
correlations between tissue sodium and GAGs have also been demonstrated in cartilage tissue –
where sodium concentrations can be as high as 250-300 mmol/L. [23,41-43] Lastly, Fischereder
et al. [31] studied the tissue sodium content of skin, muscle and arteries in 27 dialysis patients
and 21 healthy controls and found a significant association with GAG content. All these studies
suggest that NO-Na storage in tissues may be dependent on the negatively-charged density of
sulfated GAGs, an adaptable component of the extracellular matrix.

2.2.2.2

Intracellularly Stored Sodium

Bhave et al. speculated that excess sodium can also be stored intracellularly in highly
cellular tissues like muscle. [44] In this hypothesis, sodium is exchanged for potassium and other
intracellular osmolytes. To validate this theory, electrolyte balance studies in dogs revealed that
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changes in total body sodium often were accompanied by alterations in total body potassium, and
once both these cations were accounted, total body water could be closely predicted. [45]
Furthermore, in bovine cartilage, higher tissue sodium has been associated with increased density
of the Na-K-ATPase pump (the main exchanger responsible for preserving gradients for sodium
and potassium across membranes). [23] This suggests that cells may respond to the extracellular
sodium levels by altering the density of this key exchanger. Furthermore, excess sodium could be
stored in segregated intracellular compartments, while maintaining a relatively constant sodium
concentration in the main cell cytoplasm. More studies are needed to delineate the exact storage
mechanism of NO-Na.

2.2.3

Current Knowledge
Sodium concentration has been studied in several different tissues including skin, muscle,

bone and cartilage. [26,39,44,46] Table 2-1 contains approximate ranges of sodium
concentration in these tissues.

Tissue

Sodium Concentration (mmol/L)

Skin

10-60

Muscle

20-60

Bone

400

Cartilage

250-350

Table 2-1: Approximate sodium concentration in different tissues, based on previous
literature [26,39,44,46]

Several groups have studied whether this detected tissue sodium is truly osmotically
inactive, by trying to assess concentrations in the interstitial fluid of skin tissue compared to
plasma levels. Unfortunately, since the interstitial compartment consists of a GAG and collagenrich gel-like matrix - with pockets of entrapped free fluid, this fluid is not easily accessible for
analysis. [30,49] In a number of animal studies, Haljamäe and his co-workers used the liquid-
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paraffin cavity technique and micropipettes to sample nanoliters of this fluid and found higher
concentrations of sodium and potassium but lower concentrations of chloride, relative to plasma.
[50-51] Higher cation concentrations, which cannot be explained by the Gibbs-Donnan effect,
have also been found using the wick technique. [52] However, when Gilányi et al. [49] tried
replicating these results, they found that the ion distribution in the interstitium and plasma
corresponded to the Gibbs-Donnan equilibrium.
Similar contradictory findings are seen in high sodium states. Nikpey et al. looked at the
osmotic properties of interstitial fluid, lymph (derived from the interstitial fluid) and plasma in
rats on a low salt diet (controls), compared to rats with increased sodium retention - induced by
either high salt diet or deoxycorticosterone pellets. [30] These latter two groups had increased
skin sodium accumulation (higher than water accumulation), and increased skin osmolality.
Furthermore, using micropipettes, the authors found that, in all three groups, interstitial fluid,
lymph and plasma were iso-osmolar. Yet, Wiig et al. [29] used micro-dialysis and energydispersive x-ray electron microprobe analysis to find that sodium concentrations and osmolality
were higher in the rat skin tissue and lymphatic fluid compared to plasma.
There may be a number of reasons behind these discrepancies. First, the measuring
techniques are prone to experimental error due to evaporation or intracellular fluid contamination
– especially given the small sample sizes. [30,49,52] Second, the Gibbs-Donnan effect derived
from the GAGs in the interstitial space is difficult to quantify, since the GAG concentration is
dynamic. Third, multiple studies have demonstrated gradients in the osmolality and sodium
content in the skin, [24,30] suggesting that depending on the exact area sampled, different
concentrations can be obtained. More studies are needed to elucidate the exact nature of this
stored sodium in the interstitial space.
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2.3 Clinical Significance of Non-Osmotic Sodium
2.3.1

Non-Osmotic Sodium and the Immune System
The link between sodium and activation of the immune system has been known since the

1990s, when hypertonic saline was noticed to enhance cellular immune function. [53-54]
Recently, evidence has emerged that local sodium levels impact innate and adaptive immune cell
function and vice versa. [55-56]
Sodium has been shown to have a chemotaxis effect on macrophages, where higher
sodium concentrations draw these cells into the tissues. [57] Furthermore, a series of in-vitro and
in-vivo animal experiments have shown that the mononuclear phagocyte system (which includes
macrophages, monocytes and dendritic cells) respond to tissue osmotic stress by increasing the
transcription factor tonicity-responsive enhancer-binding protein (TONEBP, also known as
NFAT5), and inducing on-site vascular endothelial growth factor C (VEGF-C). [29,58-59] This
latter growth factor stimulates lymphatic hyperplasia, necessary for draining the interstitial fluid
and electrolytes back into the intravascular compartment. Lymphatic hyperplasia has been
observed with high-salt diets and sodium retention states. [29, 58-60] These lymphatic changes
were prevented by blocking the pathway at the cellular and VEGF-C levels. Furthermore,
depleting the mononuclear phagocytic system resulted in higher skin NO-Na levels in rats. [59]
Thus, it is believed that by increasing lymphatic drainage, the mononuclear phagocyte system
can influence the NO-Na levels in the tissues.
On the other hand, sodium has also been shown to have direct and indirect effects on the
immune system. In-vitro studies have shown than high sodium cultures induce pro-inflammatory
changes in T-helper and T-regulatory cells, macrophages, and dendritic cells. Furthermore, high
salt diets have been associated with increased inflammatory cytokines, and several auto-immune
conditions and infections in both animal and human studies. Lastly, sodium also affects the
intestinal microbiome, which plays a significant role in immune activation. These findings have
been previously summarized in the literature. [55-56,61-62] For the purpose of this review, we
will focus on the effect of NO-Na on the immune system from a clinical perspective.
Multiple studies have demonstrated increased levels of NO-Na – as measured by sodium
MRI technology, in infectious, inflammatory and ischemic conditions. Jantsch et al. studied
patients with lower leg bacterial cellulitis, before and after treatment, and found that the infected
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skin had higher NO-Na levels, and that antibiotic treatment decreased these levels toward those
of un-infected controls. [63] Furthermore, they looked at in-vitro macrophage elimination of
intracellular Escherichia coli and Leishmania major infections in high and low sodium chloride
media and discovered that high sodium boosted clearance of these infections through NFAT5 (or
TONEBP) activation and increased nitric oxide production. Lastly, they infected mice (fed high
and low salt diet) with Leishmania major in their footpads and found that higher tissue sodium
levels were associated with faster healing. They concluded that sodium accumulation in the skin
microenvironment may strengthen host defenses against infection.
In addition, NO-Na has been associated with ischemic conditions in the heart and the
brain. Animal studies with induced coronary ischemia and reperfusion demonstrated increased
NO-Na in the affected myocardium, corresponding to non-viable tissue, but normal values in the
hibernating tissue (penumbra). [33-35,64] Similar findings were seen in humans studied with
23

Na MRI post myocardial infarction. [65-66] Sodium levels reached a peak 4-days post infarct,

then trended down and stabilized by 90-days post. [65] After 90 days, the NO-Na level in the
damaged myocardium did not correlate with infarct age, or functional or morphological indices.
[66] Analogously, in the brain, NO-Na levels in stroke areas are elevated; yet, sodium signal in
the penumbra (tissue amenable to salvage with reperfusion therapy) is preserved. [48] These
findings suggest that ischemia may result in altered sodium content – potentially through
inflammatory effects or altered trans-cellular sodium gradients. Furthermore, in ovariectomized
rats, high salt diet and higher tissue sodium was associated with increased ischemic neurological
damage. [67]
Lastly, two main inflammatory conditions have been studied with regards to their
association with NO-Na: multiple sclerosis and scleroderma. Multiple sclerosis has been studied
by several groups, who have demonstrated increased sodium levels, not only in the demyelinated
lesions of the brain, but also in the total gray and white matter. [68-73] In addition, higher NONa levels were associated with increased disease severity and clinical disability. The increased
NO-Na in this disease may result from a combination of neuro-axonal metabolic dysfunction
(resulting in increased intracellular sodium) and interstitial inflammation. [72] Similarly,
systemic scleroderma lesions in the skin were also associated with increased NO-Na levels, and
were predictive of higher progression of disease in one year. [74]
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NO-Na and the immune system appear to be significantly interdependent based on
current evidence, and further investigations will be crucial in elucidating this relationship. Yet,
clinically, 23Na MRI technology and the relative changes in NO-Na levels already show
significant promise as diagnostic and prognostic tools in inflammatory conditions.

2.3.2

Non-Osmotic Sodium, Hypertension and the Endocrine System
The link between sodium and hypertension is long-recognized, and sodium restriction is

a common recommendation for hypertensive patients. The advent of a non-osmotic buffering
system for sodium opened up a new area of research in this field. In both animal and human
studies, hypertension (particularly refractory hypertension) has been associated with increased
skin NO-Na levels. [26,28,75] The relationship between NO-Na and blood pressure has been
extensively reviewed in the literature. [38,76-77] We will review some of the key players
affecting this relationship.
The first key player is the immune system. As discussed above, the immune system plays
an important role in regulating NO-Na by the activation of the mononuclear phagocytic system,
production of VEGF-C and lymphatic hyperplasia. Blocking this inflammatory response results
in salt-sensitive hypertension in mice and rats. [29,58-59] This suggests that the immune system
plays an important role in blood pressure regulation by altering the non-osmotic buffering system
of sodium. [26]
The second key player is the endocrine system. In the simulated space-flight experiments
looking at sodium balance in humans, 24-hour urine sodium excretion exhibited a circaseptan (7
days) and circalunar (approximately monthly) rhythmic pattern, which appeared to be under the
control of aldosterone, cortisol and cortisone levels. [16,78] Furthermore, skin sodium levels are
particularly higher in patients with hyperaldosteronism, and improve with surgical or
spironolactone treatments. [26] Aldosterone may also influence the immune response to sodium.
Dendritic cells have been found to express epithelial sodium channel (ENaC), a membrane
transporter typically under aldosterone control. [79] These findings would suggest that
aldosterone and corticosteroids impact NO-Na storage; whether directly or indirectly through
renal excretion remains to be studied.
Two other hormonal axes that have been partially studied with regards to their relation to
NO-Na include sex hormones and insulin. Multiple studies have demonstrated that sex affects

41

the amount of sodium stored in skin and muscle. [26,75,80-81] Furthermore, ovariectomy
resulted in decreased sodium storing capacity in the tissues of female rats, and greater fluid
retention. [28] In addition, insulin resistance has been shown to be associated with higher mean
arterial blood pressure in diabetics and exogenous insulin decreases the urine fractional excretion
of sodium.[82] In two studies of hemodialysis patients, increased muscle sodium levels was
associated with insulin resistance, while diabetes was associated with higher NO-Na deposition
in both skin and muscle.[83-84] These findings suggest roles for insulin, estrogen, progesterone
and testosterone that need to be further elucidated.
Thirdly, the existence of osmolyte gradients in the skin has given rise to a theory of extrarenal countercurrent system in the skin that has direct effects on blood pressure. [38,77,85] The
skin has been shown to have osmolality, urea and sodium gradients. [24,30] The similarity of
these gradients to those found in the kidney, make them particularly interesting as a novel
mechanism of hemodynamic control. Thus, blood pressure and NO-Na likely have some direct
correlation based on these osmolyte gradients in the skin, and indirect ones through multiple
hormonal axis and the immune system.

2.3.3

Non-Osmotic Sodium and Malignancy
Increased tissue sodium has been detected in neoplastic lesions (compared to normal

tissue) in the breast, prostate and brain. [86-91] In addition, pathologically more aggressive
lesions had the highest sodium concentration in prostate and brain, indicating that this index may
be of use clinically for prognostication. [88,91] In malignant lesions, the increased sodium signal
detected with 23Na MRI has been attributed to a breakdown of local cellular energy-based
sodium transporters (sodium-proton antiport and Na-K-ATPase) and sustained cell
depolarization – resulting in higher intracellular sodium levels, and increased extracellular
sodium from disruption of the necrotic tumor cells. [86,88,90-91] Unfortunately, current
knowledge is still quite limited.

2.3.4

Non-Osmotic Sodium and Degenerative Diseases
NO-Na has been associated with several degenerative conditions and structural changes

in tissues.
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In skeletal muscle, 23Na MRI was utilized to assess sodium levels in aerobic and
anaerobic exercise. [92] An increase in NO-Na was observed with anaerobic exercise only. The
authors speculated that this increase could be from higher intracellular sodium concentration due
to depletion of the Na-K-ATPase. The lack of response with aerobic exercise remains a puzzle.
Yet, increased NO-Na attributed to intracellular shifts has also been recorded in other
channelopathies, namely during cold and exercise-induced weakness in severe hyperkalemic
periodic paralysis. [93] In addition, two patients with myotonic dystrophy also had increased
sodium signal in their skeletal muscles, compared to healthy controls. [94]
In the brain, in a study of 10 patients with drug-resistant epilepsy and 27 healthy controls,
increased sodium levels were found in the epileptogenic zones (compared to irritated or noninvolved regions) in the inter-ictal state. [47] Since sodium ions are key for the maintenance of
the transmembrane gradient crucial to normal neuronal action potential, this change (in the
absence of seizure activity) was attributed to ongoing modification of the processes governing
transmembrane sodium concentrations. In fact, alterations in voltage-gated sodium channels have
been shown to be triggers in epileptic neuronal tissue. [95-97] Furthermore, increased tissue
sodium has been seen in patients with Alzheimer’s and Huntington’s degenerative disorders. [9899]
Unfortunately, the main limitation of these studies is their relatively small sample sizes
(usually less than 13 patients per group). Even so, current findings suggest that NO-Na may
serve as a diagnostic tool to identify regions of interest with structural or functional anomalies in
tissues.

2.3.5

Non-Osmotic Sodium and Sodium Surplus States: Heart and
Kidney
NO-Na has also been studied in conditions traditionally associated with increased-sodium

retention: specifically heart failure and kidney disease. Hammon et al. (2015) studied 9 patients
with acute exacerbation of congestive heart failure (CHF), before and after diuretic therapy,
compared to healthy control. [100] They found that patients had higher levels of sodium in both
skin and muscle, and that diuretic therapy significantly reduced sodium content in both these
tissues. Furthermore, water content was not reduced with treatment in muscle, but did show a
trend (p =0.06) toward decreased amount in the skin. These finding suggests that in CHF, there is
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significant NO-Na in the muscle and potentially a combination of osmotic and non-osmotic
sodium storage in the skin.
NO-Na has also been studied in renal conditions – where the ability of the kidneys to
excrete sodium may be compromised. Hammon et al. (2017) studied patients with acute kidney
injury. [101] They found that these patients did have higher NO-Na in both skin and muscle,
compared to healthy control. Yet, hemodialysis treatment did not significantly change these
levels, despite lowering blood pressure and weight. Dahlman et al. studied 33 patients on chronic
hemodialysis, and discovered that only patients older than 60years had increased skin and muscle
sodium compared to healthy controls. [102] Higher sodium levels were associated with
decreased VEGF-C. Furthermore, sodium stores in these tissues was successfully mobilized with
hemodialysis treatments.
Olde Engberink et al. have proposed that the endothelial surface layer, which tends to be
quite rich in glycosaminoglycans, may play an important role in adjusting NO-Na. [103] This
endothelial layer is itself composed of a combination of GAGs – a microenvironment highly
regulated by endothelial cells. [104] As such, this group proposed that this layer may serve as the
first layer in regulating the passage of sodium between the osmotic and non-osmotic
compartments. Furthermore, this endothelial layer is often damaged in renal disorders, [105,106]
which may explain the altered sodium handling by the kidneys in diseased conditions. Lastly,
NO-Na accumulation in CKD has been associated with end-organ damage; specifically,
increased skin NO-Na in mild to moderate CKD patients was associated with left ventricular
mass. [107]
Thus, the relationship between the kidney and sodium is likely more complicated than
previously appreciated. Sodium handling by the non-osmotic compartment and the endothelial
layer could result in renal injury, and diminished renal function may increase NO-Na – though
likely affected by other factors, like age. More studies are needed to shed more light on these
interactions and also on the effect of renal replacement therapies on this non-osmotic component.
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2.4 Conclusion
The discovery of a non-osmotic sodium buffering mechanism has resulted in a better
understanding of sodium hemostasis. Previously, sodium was believed to have a role restricted to
that of an effective osmolyte necessary for hemodynamic stability and for maintaining the
transmembrane electric potential. With the above studies, the role of non-osmotic sodium as a
key player in creating tissue micro-environments and affecting multiple signaling pathways and
biological process is becoming more obvious. More studies are needed to elucidate this
compartment further (e.g. in terms of its location – intracellular or extracellular) and reveal its
full potential. Furthermore, the use of 23Na MRI opens a door of possibilities to study this nonosmotic sodium compartment and use it in clinical medicine for diagnostic, and prognostic
purposes. Lastly, a better understanding of sodium’s multitude of roles and effects, can even lead
to new targets for therapeutic uses.
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Chapter 3

3

Non-Osmotic Sodium in CKD
This chapter contains a condensed introduction (background and the study objective and

hypothesis), as well as the main methodology, results and discussion of this thesis.

3.1 Introduction
3.1.1

Background
Sodium is a key element that plays important biological roles in several physiological

processes. For years, the paradigm of 23Na homeostasis in humans relied on the assumption that
the majority of the biologically active sodium is stored osmotically solvent in the extra-cellular
volume, and that body sodium content is regulated primarily by the kidneys. 23Na storage
independent of water retention was often neglected. Even so, multiple short and long-term
studies in humans have shown that 23Na mass balance cannot be maintained without the
existence of a non-osmotic 23Na compartment. [1-4] This compartment has further been studied
and quantified, [5-7] especially with the advent of 23Na MRI technology. [8-16] Current
evidence suggests that this non-osmotic 23Na is bound to glycosamino-glycans (GAGs) in the
extracellular matrix of tissues. [17-21] Sodium deposition has been linked to multiple
physiological and pathological processes including: exercise, hypertension and
hyperaldosteronism, congestive heart failure, malignancy, inflammation, and ischemia. [6-7,911,13,21-23]
Sodium homeostasis is fundamentally altered in patients with kidney disease – due to the
lack of renal sodium excretion. [30-33] As such, patients with chronic kidney disease may have a
higher utilization of this non-osmotic 23Na buffering system. Previous studies have demonstrated
increased skin and muscle 23Na in patients undergoing acute hemodialysis treatment and those
older than 60 years on chronic HD – relative to healthy controls. [10,12] Even so, in a cohort of
patients with stage 1-3 of kidney disease, Schneider et al. did not find a correlation between
estimated glomerular filtration rate (eGFR) and skin 23Na. [14] The effect of the severity of
kidney disease on the non-osmotic 23Na accumulation in tissues of patients has yet to be
determined.
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3.1.2

Study Hypothesis and Objective

The objectives of this thesis are:
1) To use 23Na MRI technology to examine the sodium deposition in skin, muscle and
skeleton tissues of two groups of CKD patients: 1) CKD stage 4-5 (not dialysis)
patients, and 2) dialysis patients – sub categorized into PD and in-center HD, and
compare this deposition with controls with normal kidney function.
Hypothesis: Since the kidney plays a key role in regulating sodium content in the body, and since
patients with CKD have altered sodium excretion, we hypothesized that CKD patients would
have higher levels of non-osmotic sodium in their tissues. In addition, we hypothesized that the
degree of non-osmotic sodium would be dependent on the stage of kidney function, i.e. patients
with end-stage kidney function on renal replacement therapy would have more sodium in their
tissues than patients with stage 4-5 CKD (not on dialysis). Also, since peritoneal dialysis patients
tend to have higher residual renal function, we speculated that they would have lower sodium
levels than patients on in-center hemodialysis.

2) To explore associations between sodium deposition in these tissues with baseline
characteristics and biochemical markers, to explore specific correlations.
Hypothesis: Given the many associations between non-osmotic sodium and physiological
functions (discussed in Chapter 2), we suspected that sodium accumulation may be associated
with some of the pathophysiological changes observed in the CKD patients.
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3.2 Methods
3.2.1

Study Design
This is a pilot cross-sectional cohort study of patients with different levels of kidney

disease: CKD 4-5 not on dialysis (CKD group), and dialysis - peritoneal dialysis (PD) and
hemodialysis (HD); compared to controls with normal kidney function (Control group). During
the study sessions, we obtained baseline characteristics (including age, sex, past medical history,
medications, and renal history), blood work for biochemical analysis, and MRI study of the right
lower leg, for each participant.
This study was approved by the University of Western Ontario Health Sciences Research
Ethics Board and was conducted in compliance with the approved protocol, Good Clinical
Practice Guidelines and all applicable regulatory requirements.

3.2.2

Subjects
Controls from London, Ontario, and CKD and dialysis (both PD and HD) patients from

London Health Sciences Centre – Regional Renal Program participated in the study. All
participants had to be 18 years or older and provided written informed consent prior to the study.
Subjects were considered controls if they lacked any history of kidney disease, heart failure, liver
cirrhosis or peripheral edema. This group was recruited through posters advertising the study in
the London community (hospitals and churches). CKD patients had to have CKD Stage 4-5
disease (as defined by Kidney Disease: Improving Global Outcomes 2012 Guideline [34]) and
no indications to start dialysis. Dialysis patients included PD and in-center thrice-weekly HD
patients who had been established on their respective dialysis modality for at least 3 months.
Subjects were excluded if they were pregnant, breast-feeding, intending pregnancy or unable to
provide consent, or if they had any contraindication to MRI studies.

3.2.3

Biochemical Measurements
Plasma, serum and blood specimens from each subject were collected, processed and

analyzed by a central laboratory (London Health Sciences Centre, London, Canada) for routine
clinical chemistry of a core set of parameters. eGFR values were estimated using the Chronic
Kidney Disease Epidemiology Collaboration formula. [35]
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3.2.4

Sodium MRI Quantification of Tissue Sodium
Tissue 23Na concentration in the lower leg tissues was assessed non-invasively using MRI

technology, similarly to previously described methods. [8-9] This technology has been
previously validated against sodium quantification with chemical analysis by ashing, [8] and has
been found to be reliable. [36] A multinuclear-capable 3.0-T MRI (Discovery MR750, General
Electric Healthcare, Milwaukee, WI) was used to acquire proton and sodium images. Subjects
were positioned supine in the magnet bore with the right lower leg (10-15 cm below the knee)
centered in a custom-made 12-rung 18-cm-diameter 23Na birdcage radiofrequency (RF) coil (Fig.
3-1). Calibration vials with 10, 20 and 40 mmol/L of saline were placed in the RF coil, over the
subjects’ shins. Axial proton T1-weighted images with a fast-low-angle-shot (FLASH) sequence
were acquired to delineate the anatomy of the lower leg. A single-slice 23Na MR image was
obtained with a density-adapted three-dimensional radial projection reconstruction pulse
sequence optimized for sodium acquisition, [37] with the following parameters: slice-selective
RF pulse with a 90° flip angle, TR/TE: 100/1.5ms, total acquisition time: 30min, number of
signal averages: 100, slice-thickness: 30mm, and isotropic field of view/resolution: 18/0.3 cm2.

Figure 3-1: Custom-made RF coil and position of the right leg in the MRI.
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Maps of tissue 23Na concentration were generated with Matlab (Mathworks, Natick,
USA, R2018a), using the calibration vials relating signal intensity to 23Na concentration using
linear trend analysis. 23Na concentration maps were superimposed with the proton anatomical
images to delineate the regions of interest. Four regions of interest (ROIs) were drawn, using
OsiriX Lite (Version 9.5.2) software, highlighting different tissues: 1) pre-tibial skin, 2) posterior
leg skin, 3) soleus muscle, and 4) tibia (including bone marrow) (Fig. 3-2). Two skin regions
were included - based on reproducibility, because 23Na distribution in this tissue was relatively
inhomogeneous. This inhomogeneity in sodium content could make one of these areas more
clinically relevant. In addition, the bone marrow was included in the tibia ROI because the
sodium signal from the bone marrow and the osseous tissues were comparable in our preliminary
analysis (data not shown). 23Na concentration in these four regions was recorded for analysis.

Pre-tibial Skin
Tibia

Soleus
Posterior-Leg Skin

Figure 3-2: Sample overlap image with sodium MRI image (gray scale) and proton image
(red scale) superimposed together and the four regions of interest (ROIs) highlighted.
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3.2.5

Data Analysis
Statistical analysis was performed using SPSS Statistics, Version 23 (IBM, Chicago).

Data were analyzed using descriptive statistics (means with standard deviation (SD) or 95%
confidence intervals (CI) for continuous variables; percentages for categorical variables).
Kruskal-Wallis, Anova and Fisher’s exact tests were used to compare groups across baseline
characteristics. Mann-Whitney and t-tests were applied to unpaired observations. Correlations
were assessed by calculating Pearson (r) and Spearman (rho) correlation coefficients. We then
performed some exploratory multiple regression analysis to examine the parameters that
independently influence tissue 23Na concentration. The basic regression models were generated
using age, sex, and the parameter with the strongest correlation (r or rho) from each of the main
areas: inflammation, bone mineral disease, and blood pressure. Other variables with strong
correlation (p<0.01) were then added to the basic model sequentially. F-statics were used to
remove factors who did not significantly contribute to the model. The models were compared
using corrected R2 coefficient. Due to the exploratory nature of these models, interactions
between the factors were not assessed. Furthermore, these parameters were not adjusted for renal
function. Missing data were managed by removing that subject from that particular analysis.
Two-tailed p-values <0.05 were considered statistically significant.
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3.3 Results
In total, 10 Control, 12 CKD, and 23 dialysis (10 PD and 13 HD) subjects participated in
the study (Fig. 3-3). 56% of all participants were male and 84% were Caucasian. Table 2-1
highlights the baseline characteristics of these groups. CKD and dialysis subjects were older and
had higher weights and BMIs. As expected, they also had higher rates of comorbidities
including: hypertension, atherosclerosis, and congestive heart failure. Correspondingly, subjects
with kidney disease had significantly higher use of anti-hypertensive medication and other renalspecific medications (erythropoietin-stimulating agents and phosphate binders). The main
etiologies of renal disease included hypertension, diabetes mellitus, reno-vascular conditions,
glomerulonephritis and other (some subjects had multiple etiologies). The three groups also
varied across multiple serum biomarkers – most of which are explained by the presence of
kidney disease. Notably, serum sodium was different among the groups, with means of
141mmol/L, 139.9mmol/L and 138.3mmol/L in the Control, CKD and dialysis groups (PD and
HD) respectively (p-value 0.01).

10 Controls
27 Dialysis Patients
12 CKD Patients

Withdrawn:
2 HD patients - withdrew consent

2 HD patients - too unwell

23 Dialysis Patients:
10 Controls

12 CKD Patients

- 10 Peritoneal Dialysis
- 13 Hemodialysis

Figure 3-3: Study Population: including recruited participants who were withdrawn, and
the ones included in the study.
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When comparing the PD and HD subgroups (Table 3-1), PD subjects had higher residual
renal function (means of 1175ml vs 220ml, p-value 0.003), and higher use of diuretic therapy
(100% vs 23.1%, p-value <0.001). These two subgroups also varied in a number of serum
biomarkers, consistent with the different clearance-characteristics of these dialysis modalities.
PD subjects had statistically significant higher creatinine and lower albumin concentrations.
Lastly, HD participants had higher hemoglobin levels compared to PD ones, 120.3 g/L vs 104.0
g/L respectively (p-value 0.01). High sensitivity C-reactive protein (CRP) was not statistically
different between the two.
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Table 3-1: Baseline characteristics for the three study groups, and for the two subgroups (HD and PD).
Parameter

Control (n=10)

CKD (n=12)

Dialysis (n=23)

p-value

HD (n=13)

PD (n=10)

p-value*

53.3 (19.4)

66.3 (6.7)

61.6 (9.4)

0.04

62.5 (9.1)

60.3 (10.2)

0.59

Sex, men/women

4/6

8/4

14/9

0.52

9/4

5/5

0.42

Race, Caucasian/other

8/2

12/0

18/5

0.228

8/5

10/0

0.046

Height, cm, mean (SD)

167.3 (7.0)

166.4 (9.8)

170.8 (7.7)

0.24

171.2 (7.5)

170.3 (8.4)

0.78

Weight, kg, mean (SD)

70.5 (8.2)

88.5 (18.6)

83.5 (18.7)

0.047

83.9 (22.6)

83.1 (13.0)

0.92

BMI, kg/m2, mean (SD)

25.2 (2.7)

31.7 (4.5)

28.6 (6.1)

0.02

28.4 (7.0)

28.8 (5.0)

0.89

10.0

91.7

87.0

<0.001

100.0

70.0

0.07

Atherosclerosis, %

0

50.0

43.5

0.02

46.2

40.0

1.00

Coronary artery disease, %

0

16.7

21.7

0.36

30.8

10.0

0.34

Cerebrovascular disease, %

0

16.7

13.0

0.58

15.4

10.0

1.00

Peripheral vascular disease, %

0

8.3

13.0

0.80

15.4

10.0

1.00

Age, year, mean (SD)

Comorbidities
Hypertension, %
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Congestive heart failure, %

0

0

26.1

0.04

30.8

20.0

0.66

10.0

58.3

43.5

0.053

46.2

40.0

1.00

0

0

17.4

0.16

23.1

10.0

0.60

Hypertensive nephropathy, %

-

41.7

44.5

0.04

38.5

50.0

0.69

Diabetic nephropathy, %

-

33.3

39.1

0.06

38.5

40.0

1.00

Glomerulonephritis, %

-

16.7

8.7

0.54

15.4

0

0.49

Vascular nephropathy

-

25.0

39.1

0.053

46.2

30.0

0.67

Other

-

41.7

30.4

0.06

30.8

30.0

1.00

Dialysis vintage, months, mean (SD)

-

-

37.1 (34.3)

-

47.1 (41.7)

24.2 (14.8)

0.09

Residual renal function, ml, mean (SD)

-

-

635 (721)

-

220 (326)

1175 (746)

0.003

Diabetes Mellitus, %
COPD, %

Etiology of Kidney Disease

Medications
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Anti-hypertensives, %

10.0

91.7

78.3

<0.001

84.6

70.0

0.62

ACEI/ARB, %

10.0

58.3

30.4

0.053

30.8

30.0

1.00

Diuretic, %

10.0

58.3

56.5

0.03

23.1

100.0

<0.001

Beta blocker, %

0

66.7

65.2

0.001

76.9

50.0

0.22

Calcium channel blocker, %

0

41.7

52.2

0.01

46.2

60.0

0.68

ESA, %

0

25.0

60.9

0.001

69.2

50.0

0.42

Phosphate binders, %

0

33.3

87.0

<0.001

84.6

90.0

1.00

Calcium Binders, %

0

33.3

82.6

<0.001

76.9

90.0

0.60

10.0

66.7

39.1

0.003

38.5

40.0

1.00

141 (2.2)

139.9 (1.8)

138.3 (2.8)

0.01

138.4 (2.6)

138.1 (3.2)

0.81

eGFR, ml/min/1.73m2, mean (SD)

88.1 (16.1)

23.1 (11.8)

-

<0.001

-

-

-

Creatinine, µm/L, mean (SD)

77.0 (12.2)

257.3 (83.5)

630.7 (242.3)

<0.001

557.7 (215.3)

718.3 (254.3)

0.13

Albumin, g/L, mean (SD)

43.7 (2.5)

43.3 (2.4)

39.0 (4.4)

0.002

41.2 (3.6)

36.7 (4.0)

0.02

142.9 (12.8)

117.3 (22.7)

112.9 (16.1)

0.001

120.3 (15.2)

104.0 (12.6)

0.01

Aspirin, %

Serum Biomarkers
Sodium, mmol/L, mean (SD)

Hemoglobin, g/L, mean (SD)
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CRP, mg/L, mean (SD)

2.2 (2.6)

2.9 (2.4)

13.7 (16.9)

<0.001

15.8 (22.1)

10.6 (7.3)

0.46

PTH, pmol/L, mean (SD)

4.5 (1.2)

18.8 (16.9)

40.7 (40.3)

0.001

44.8 (42.9)

35.9 (38.7)

0.62

hsTroponin T, ng/L, mean (SD)

5.5 (3.2)

27.8 (16.9)

130.1 (157.4)

<0.001

165.2 (196.7)

88.0 (83.3)

0.24

p-value* - comparing HD and PD; p-values calculated with Fisher’s exact test.
ACEI – Angiotensin converting enzyme inhibitor, ARB – Angiotensin II receptor blocker, BMI – Body mass index, COPD – Chronic
obstructive pulmonary disease, CRP – high sensitivity C-Reactive protein, eGFR- Estimated glomerular filtration rate – using CKDEPI equation, [35] ESA – Erythropoietin stimulating agent, hsTroponin T – High sensitivity troponin T, PTH – Parathyroid hormone,
SD- standard deviation
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Figure 3-4: Examples of sodium concentration maps for the different study groups:
control, CKD, HD and PD. (Colour map on the side indicates the sodium concentration in
mmol/L)
Four representative examples of tissue 23Na concentration maps are shown in Fig. 3-4. The
23

Na concentration in the study groups for the four regions of interest is shown in Fig. 3-5. 23Na

levels were statistically higher in dialysis subjects compared to healthy controls (p<0.05) across
all tissues. No statistically significant difference was found between 23Na levels in dialysis and
CKD subjects. CKD participants had statistically significant higher 23Na levels in their tibia and
posterior leg skin compared to controls. Furthermore, when the dialysis group was split into HD
and PD subgroups, no difference was found between PD, HD and CKD. Yet, all three had higher
23

Na in the tibia and posterior leg skin compared to the control group. Only PD subjects had

statistically higher 23Na than controls in the soleus muscle and pretibial skin.
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A

B

Figure 3-5: Tissue Sodium Concentration in the study groups. A – results for the main
three groups (Control, Dialysis and CKD), and B – results when PD and HD patients
are separated.
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Correlations between 23Na levels in the four tissues, and different subject parameters
were also explored (Table 3-2). Multiple statistically significant correlations were discovered
between 23Na levels and baseline characteristics, medications, and renal, inflammatory, mineral
bone disease and end-organ markers. Some correlations were persistent across the four tissues
studied (e.g. correlations with parathyroid hormone, high sensitivity troponin T and
inflammatory markers). Conversely, some parameters were associated with 23Na levels only in
specific tissues (e.g. increased age was associated with higher 23Na in soleus and posterior leg
skin only). Serum sodium levels did not correlate with 23Na concentrations of any of the tissues
studied.
Multi-variable regression linear models are shown in Table 2-3. Tibia and soleus 23Na
levels were explained relatively well by the third models (R2 0.713 and 0.603, respectively). The
models for pretibial and posterior leg skin were weaker (models 2 had R2 0.274 and 0.456,
respectively). These models were not improved by the addition of other parameters (including
age (when not already included), sex, hypertension, and eGFR; data not shown). Each tissue had
its own set of parameters contributing to the models.
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Table 3-2: Correlations between Sodium deposition in the tissues and subjects’ baseline characteristics, medications and
serum markers.
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Corr. Coeff. – Correlation coefficient, ALP – Alkaline phosphatase, CHF – Congestive heart failure, COPD – Chronic obstructive
pulmonary disease, CRP – high sensitivity C-Reactive protein, eGFR- Estimated glomerular filtration rate – using CKD-EPI equation,
[35] ESA – Erythropoietin stimulating agent, hsTroponin T – High sensitivity troponin T, INR – International normalized ratio, PTH –
Parathyroid hormone.
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Table 3-3: Linear regression models for explanation of 23Na in the different tissues studied.
Tibia

Parameter
Hemoglobin

Model 1

Model 2

Model 3

R2 0.474

R2 0.670

R2 0.713

Beta Coeff.

p-value

-0.689

Beta Coeff.

<0.001

PTH

p-value

Parameter
Albumin

p-value

-0.504

<0.001

-0.367

0.003

0.479

<0.001

0.479

<0.001

-0.249

0.030

Albumin
Soleus

Beta Coeff.

Model 1

Model 2

Model 3

R2 0.450

R2 0.528

R2 0.603

Beta Coeff.

p-value

-0.677

Beta Coeff.

<0.001

PTH

p-value

Beta Coeff.

p-value

-0.620

<0.001

-0.547

<0.001

0.270

0.021

0.291

0.008

0.283

0.011

Age
Post-Leg
Skin

Parameter
Hypertension

Model 1

Model 2

R2 0.304

R2 0.456

Beta Coeff.

p-value

0.551

Beta Coeff.

<0.001

COPD
Pretibial Skin

Parameter
Hemoglobin

0.455

0.001

0.402

0.003

Model 1

Model 2

R2 0.178

R2 0.274

Beta Coeff.
-0.422

p-value

Beta Coeff.

0.010

Age

p-value

p-value

-0.356

0.025

0.317

0.045

Beta coeff. – standardized coefficient
PTH – Parathyroid hormone, eGFR- Estimated glomerular filtration rate – using CKD-EPI
equation,35 COPD - Chronic obstructive pulmonary disease.
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3.4 Discussion and Conclusions
In our study we found that there was a statistically significant increase in 23Na
accumulated in the tissues of dialysis patients compared to controls with normal kidney function.
Evidence of sodium accumulation was observed even in CKD patients (even if not always
statistically significant). No statistically significant difference was found in the 23Na levels
among CKD, PD and HD participants. In addition, we found significant associations between
23

Na levels and markers for mineral bone disease and inflammation. Even so, the major

contributing parameters were tissue specific.

3.4.1

Age and Sex, and Sodium
In healthy controls, sex and age have been correlated to skin and muscle 23Na levels.

[9,38] Age has also been associated with higher 3Na deposits in the skin of patients with mild
CKD. [14] The effect of age on hemodialysis patients has been inconsistent. Dahlmann et al.
[10] showed increased skin 3Na in older subjects, while Fischereder et al. [20] did not observe an
age-related effect. As demonstrated in Tables 3-2 and 3-3, age did correlate with 23Na deposition
in the posterior-leg skin, soleus and tibia, however this effect lost its statistical significance in the
multivariable regression models. An opposite phenomenon was observed between age and
pretibial skin. These inconsistencies suggest a need for larger in-depth studies.
There were no observed changes in 23Na deposition in the tissues based on sex. Similarly,
Fischereder et al. did not detect a difference in 23Na deposition based on sex, in hemodialysis
patients. [20] Even so, Schneider et al. showed that in patients with mild CKD, male sex was
associated with significantly higher levels of skin 23Na. [14] We postulate that the sex-effect may
be overshadowed by the altered pathophysiology in severe CKD. Since the majority of our
participants had CKD - Stages 4-5D, we speculate that in this population, CKD- related factors
may supersede the effect of sex on non-osmotic 23Na deposition in the tissues.

3.4.2

CKD and Sodium
Our study found an increase in 23Na accumulation in dialysis and CKD patients relative

to controls in all tissue types, not just skin and muscle. This is the first study that has reported on

72

measurement of sodium levels in osseous tissue with23Na MRI, and found increased sodium
deposition even in this compartment.
While the groups were statistically different with regards to their measured serum sodium
(Table 3-2), controls had the lowest tissue 23Na concentrations despite having the highest serum
sodium levels. This confirms that tissue and serum sodium are not correlated. Our skin and
muscle 23Na concentrations were similar in range to previously reported values (range of 10-50
mmol/L).[10,12,14]
Hammon et al. found similarly higher sodium accumulation in the skin and muscle of
new-hemodialysis-start patients compared to healthy controls. [12] However, two other groups
did not show a difference between 23Na deposition in the skin and muscle of HD patients versus
controls. [10.20] This discrepancy may be due to the different populations studied, with previous
studies focusing solely on HD patients, as opposed to both HD and PD patients. Our study is the
first one to include PD and CKD stage 4-5 patients. Yet, even when we compare the HD
subgroup and controls, 23Na in the soleus muscle and posterior leg skin is still significantly
higher. All these studies are relatively small, involving less than 30 HD patients. Larger studies
are needed to resolve the different findings.
Of note, while eGFR and creatinine had statistically significant correlations with tissue
23

Na (Table 3-2), when these parameters were added to the regression models, the b-coefficients

were not statistically significant (data not shown). Furthermore, both of these parameters are
difficult to interpret in the setting of dialysis, since both PD and HD will affect these values. As
such, these data should be interpreted carefully. It is difficult to determine from our data if
kidney function has a direct or indirect (by altering inflammation and other parameters) effect on
sodium levels, or if these results are due to confounding factors.

3.4.3

Inflammation and Sodium
Our study did demonstrate significant correlations between the measured inflammatory

markers (CRP, albumin and hemoglobin) and tissue 23Na deposition – and all but two of these
associations were statistically significant (Table 3-2). The correlations of inflammatory markers
with muscle and bone and posterior leg skin 23Na appear to be more robust – persisting even in
the linear regression models. This finding is consistent with pre-existing literature, where nonosmotic sodium is closely related to inflammatory states and immune activity. [7,24,27,39-43]
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Even so, these correlations were not adjusted for renal function, and their interpretation is
limited.

3.4.4

Mineral Bone Disease and Sodium
The existence of non-osmotic sodium storage in osseous tissue has been known since the

1950s. [44-47] Even so, previous studies of 23Na in humans have not looked at osseous tissue due to the assumption that this 23Na reservoir is less responsive to acute physiological and
pathological changes. [48-49] Yet, CKD is a chronic process, allowing for 23Na equilibration
across the multiple 23Na compartments. Furthermore, CKD patients often have altered mineral
bone physiology due to mineral bone disease and increased bone turnover (except in patients
with adynamic bone disease). [50-51] The presence of mineral bone disease (MBD) (and its
variations) make bone 23Na levels in this population a clinically relevant outcome.
In our study, we found that biomarkers of MBD had significant associations, not only
with 23Na deposition in the tibia, but also with non-osmotic 23Na in the skin and muscle (Table 32). These associations persisted for soleus and tibia 23Na even after adjusting for other
confounders (Table 3-3). These associations can be explained by the existence of multiple
sodium-dependent phosphate transporters in bone, renal and intestinal tissues, which are
regulated by the parathyroid hormone, 1,25-dihidroxy-Vitamin D and fibroblast growth factor
23. [52-53] Thus, sodium and phosphate homeostasis are closely intertwined, and MBD markers
may have a role in 23Na deposition in tissues. Whether sodium levels in the bones is affected by
the degree of mineral bone disease, or CKD level is still unclear.

3.4.5

Cardiopulmonary System and Sodium
CKD patients have high rates of cardiovascular mortality. [54-55] The correlation of skin

3

Na and cardiac findings in patients with CKD has been previously looked at by Schneider et al.

[14] This group demonstrated that 23Na in the skin of 99 patients with CKD stages 1-3 was
associated with MRI evidence of left ventricular hypertrophy. [14] In our study, we used
troponin T as a surrogate marker of cardiovascular health, since troponitis has often been
associated with worse prognosis in CKD. [56-60] Increased troponin T levels were associated
with higher non-osmotic 23Na in all regions studied (Table 3-2), suggesting that 23Na
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accumulation may play a role in end-organ damage; potentially via its immune-modulating
effects. [24,39-43] However, these associations were not statistically significant in our regression
models. As such, based on current evidence, no clear conclusions can be derived on the link of
tissue 23Na and serum troponin T levels.
Primary and secondary hypertension (another cardiovascular risk factor) has often been
associated with increased skin and muscle 23Na in non-CKD patients. [8,9,26,61] In contrast, in
patients with mild CKD (Stage 1-3), Schneider et al. only demonstrated a trend of higher skin
23

Na and hypertension, which did not reach statistical significance (p-value 0.07). [14] Our data

shows a similar (albeit statistically significant) association between the clinical diagnosis of
hypertension in CKD and 23Na levels in the posterior-leg skin, soleus and tibia. Even so, we did
not adjust for renal function and other potential confounders.
The association between COPD and sodium deposition in the posterior leg skin was an
unexpected finding. We postulate four different hypotheses that may explain it. First. since
patients with COPD have a significant history of smoking, and fat-soluble toxins can be stored in
subcutaneous fat, this pro-inflammatory milieu may be responsible for the increased 23Na skin
content. Even so, no correlation was found between current or previous smoking history (latter
defined as 20 pack-years or more) and tissue 23Na (data not shown). Second, dialysis and CKD
patients may have pulmonary edema which is misdiagnosis as COPD. [62] Increased pulmonary
edema would suggest a sodium abundance and an increase use of non-osmotic sodium buffers.
Third, sodium deposition may also occur in the airways of the respiratory system – causing
inflammation and hyper-reactivity, which in the CKD population may be labelled as COPD. [62]
Fourth, this finding could be secondary to chance (given the p-value of 0.05), or other types of
bias.
Sodium deposition in the skin, muscle and bone has the potential to provide significant
clinical information on different organ systems due to its many associations (be they a result of
cause, consequence or confounding). More studies will be needed to unlock the full potential of
this novel measurement.

3.4.6

Inter and Intra – Tissue Differences
Another important finding from our pilot study is that the 23Na levels in each tissue

appear to be associated with a unique combination of parameters. This finding is outlined in the
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different parameters in the regression models in Table 2-3. While alterations in tibia and soleus
23

Na can be affected by albumin and PTH levels, these two parameters do not have a statistically

significant effect on skin 23Na. Bone and muscle 23Na levels appear to have a stronger link with
inflammatory and MBD markers, as evidenced by the higher correlation coefficients and lower
p-values. Conversely, diabetes mellitus was found to only play a role in skin 23Na.
Differences between tissues has been previously documented by Schneider et al. who
found that skin but not muscle 23Na was associated with left ventricular hypertrophy. [14] In
addition, Wang et al. showed that men have higher accumulation of 23Na in the skin vs muscle,
while for women 23Na accumulation has the opposite pattern. [15] In contrast, a number of other
studies have demonstrated that skin and muscle 23Na are similarly affected by diabetes mellitus,
age, vascular endothelial growth factor levels, end-stage kidney disease, hyperaldosteronism and
hypertension. [8,9,12,63] Compared to these latter studies, our study included a more extensive
test for correlations between the 23Na levels of the tissues and a variety of parameters.
Furthermore, the previous studies’ populations varied significantly, from healthy individuals and
hypertensive patients, to patients on hemodialysis.
Our study is also unique in highlighting the heterogeneity of 23Na deposition in skin. This
heterogeneity can be qualitatively discerned with the naked eye (Fig. 3-4). Accounting for this
effect, we intentionally looked at two different skin regions (pretibial skin and posterior leg
skin), and the correlations between the 23Na in these two regions with other parameters were
quite variable (Table 3-2 and 3-3). In general, post-leg skin associations tended to be more
statistically robust; e.g. hypertension was significantly associated with an increase in posterior
leg skin 23Na (correlation coefficient 0.547, p-value <0.001), but not with pretibial skin 23Na
(correlation coefficient 0.219, p-value 0.548). Such a wide difference in p-values suggest a true
divergence, as opposed to a measurement error or a statistical accident.
Skin heterogeneity has not been reported in previous studies, the majority of which do
not indicate if the 23Na signal corresponds to a specific skin region. [8-10,14-15,22,64] Similar to
this work, in their study, Kopp et al.63 used the posterior leg skin in their measurements. Even so,
expanded studies are needed to elucidate both the local factors in tissue 23Na storage and the
sodium signal (either the average signal or the one from a specific skin region) that best
corresponds to clinically significant outcomes.
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These inter and intra-tissue divergences alludes to the existence of both macro and microenvironmental factors that likely play a role in the regulation of non-osmotic sodium storage via alterations in the GAG components of the extracellular matrix. [18-20] Potential factors
include local dysregulation, inflammation and ischemia. [7,13,24,27,41-42]

3.4.7

Limitations
Our study did have several limitations. Since it was a cross-sectional observational study,

causality effects cannot be determined. Measured and unmeasured confounding factors could be
responsible for the differences in sodium levels of tissues, as well as the associations detected.
Furthermore, we did not adjust for kidney function in our assessment of these associations.
As a pilot study, the number of subjects in our study groups was relatively modest
(ranging from 10 to 23). Thus, generalizability of our data to all severe CKD patients should be
done cautiously until larger studies can be conducted. Even so, several statistically-robust
associations were discovered, despite the small sample size, adding validity to our results.

3.4.8

Discussion and Conclusions
In our study, we observed that dialysis patients had significantly higher 23Na level in their

skin, muscle and bone tissues compared to controls with normal kidney function. Even CKD
patients (not on dialysis) had evidence of sodium accumulation - albeit not always statistically
significant. No significant difference was found in the tissue 23Na levels of HD, PD and CKD
groups. These levels correlated strongly with markers of mineral bone disease and inflammation,
while the effect of age and sex seemed relatively limited. Yet, associated factors appeared to be
tissue specific. More studies are needed to elucidate the effect and clinical utility of non-osmotic
sodium in tissues.
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Chapter 4

4

Conclusions and Future Work
This chapter contains a summary of the achievements in this thesis, as well as the

limitations of this research. Furthermore, future directions of research will be explored.

4.1 Discussion
4.1.1

Summary of Thesis Work
Our study investigated non-osmotic tissue sodium levels in patients with different

severity of kidney disease (CKD, PD and HD) compared to controls. The results indicated that
patients on dialysis have statistically higher sodium levels in all three tissues: skin, bone and
muscle. No difference was detected between subjects with CKD (not on dialysis) and subjects on
dialysis, and CKD patients also showed trends toward sodium accumulation – albeit not always
statistically significant, relative to controls.
Furthermore, we studied the associations between tissue sodium and previously
recognized clinical factors in non-osmotic sodium build-up (see Chapter 2), as well as other
complications of kidney disease. We did find significant correlations with inflammatory markers
and mineral bone disease. The correlations with specific factors were found to be tissue specific:
soleus and tibial sodium was strongly correlated with mineral bone disease and inflammatory
markers, while skin sodium was better correlated with hypertension.
The main contribution of this study to the existing literature is additional information in
the evolving field of non-osmotic sodium storage. The study adds to the current knowledge of
NO-Na specifically in renal patients. Previous literature has looked at patients with mild to
moderate levels of CKD and acute or chronic patients on hemodialysis. [1-3] Yet, our study is
the first to report on patients with CKD 4-5 and on peritoneal dialysis. PD patients are often
healthier than HD patients, due to the inherent independence required by this modality. Yet,
despite our initial hypothesis that PD patients would have lower levels of tissue sodium because
of their preserved residual renal function, no significant difference was observed based on
dialysis modality. No statistically significant difference was observed in tissue sodium between
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CKD and dialysis patients, either. Even so, there was a trend of lower sodium in CKD patients,
which may reach statistical significance with larger sample sizes.
Similar to previous studies, we did find an association with CKD and increased tissue
sodium. Yet, due to the observational nature of the study, causes or consequences cannot be
ascertained.
Our methodology was similar to those of previous studies – namely utilizing 23Na MRI
technology to measure absolute sodium content. [4,5] This study does not help distinguish intracellular vs extra-cellular sodium, or bound vs unbound states. The 23Na MRI pulse sequences
detected sodium density levels. Even so, we do report on sodium levels in the tibia (osseous and
bone marrow tissue) – as well as the previously reported muscle and skin tissue. Osseous sodium
content measured with 23Na MRI technology has not been previously described. Yet, given the
physiology and the principles underlying this technology, we have no reason to suspect that
sodium measurements in bone would be inaccurate.
This study also highlights the heterogeneity of non-osmotic sodium storage, both inter
and intra-tissue. This finding is in keeping with the current view in the literature of an adaptable
non-osmotic sodium reservoir based on glycosaminoglycan content. [6,7] Many different factors
including the immune system, structural abnormalities, and ischemia (refer to section 2.5) could
play a role in the micro-environment and regulate the capacity of this storage system.
Furthermore, differences between sodium levels in the skin and muscle tissues has been
previously noted. [1,8] The results from our study indicate that biochemical factors affecting
sodium storage may be tissue-dependent - a relatively novel hypothesis.
Since this study looked at clinically significant markers – including laboratory markers
and baseline characteristics, it highlights some of the possible interactions between non-osmotic
sodium and these clinical factors in the study population. These association are hypothesisgenerating and may direct further investigations to shed light into the pathophysiology and
consequences of non-osmotic sodium storage. In accordance with the published literature, which
show an interdependent relationship between sodium and immune activation, [9-12] a link was
demonstrated between inflammatory markers and sodium levels. Similar associations were found
with markers of cardiovascular disease and bone mineral disease.
In current literature, osseous storage of sodium is believed to be more static. [13] Yet,
due to the chronicity of CKD and dialysis, in our study, sodium stores in the tibia were also

83

noticed to be higher than controls. This fact could be explained by the increased metabolic
activity of bone in CKD, due to mineral bone disease. Even so, our ability to perturb this osseous
compartment with current treatments (diuretics or dialysis) is unclear. Similarly, more studies
will be needed to assess the effect of treatments in sodium levels in the skin and muscle.
Our study highlighted clinical correlations of non-osmotic sodium in patients with kidney disease
and adds to the current body of knowledge. Yet, more studies will be needed to understand
sodium metabolism and use it for diagnostic and therapeutic purposes in the future.

4.1.2

Study Limitations
This study also had several limitations. First, this was a pilot study, and as such, the study

populations (Control, CKD, HD and PD) were relatively small – maximum of 13 subjects for
HD. These population sizes make generalization of the results to all patients with CKD a
cautious endeavor. Furthermore, the control group did have some comorbidities (for e.g. diabetes
mellitus and hypertension), which do affect sodium metabolism and sodium deposition
(potentially decreasing the measured effect from kidney function). While it is reassuring that
statistically significant trends were detectable even with these sizes and a control group that was
not completely healthy, these results need to be demonstrated in larger clinical trials. As a pilot
study, the purpose of this research was to roughly test the validity of our hypothesis, before more
resource-intensive studies are undertaken. Large studies would be quite financially burdensome –
since MRI technology is a relatively expensive imaging modality.
Second, certain aspects of our methodology could be strengthened. The power of the
study could have been increased by having completely healthy controls, or sex and age matching the control group to the patient groups. In addition, our assessment of osseous sodium
levels included the bone marrow tissue. As such, the sodium signal detected consists of the
average from both these tissues. Ideally these two tissues should be looked at separately, in
future studies. Furthermore, when estimating the kidney function of dialysis patients, instead of
using creatinine and eGFR, a more appropriate measure, such as the average of urea and
creatinine clearances (from 24hour urine collections) could be used. Also, the associations and
regression models between tissue sodium and other parameters did not adjust for potential
confounding factors. As such, in future studies, more detailed statistical analysis will be
necessary to try and assess the main parameters that play a role in tissue sodium.
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Thirdly, as an observational study, this research has the inherent limitations of this genre
of research. Primarily, causality cannot be established, and only associations (prone to
confounding factors) can be generated. Randomized control trials would be the ideal study for
showing causality, but unfortunately, these studies would be challenging and unethical to
perform in humans in clinical settings. A proper randomized trial would require randomizing
individuals to different levels of CKD, and then measuring sodium levels in the tissues – an
unethical process given the high burden of morbidity which would be carried by participants.
Fourthly, similar to other clinical studies, sampling error in the population induces further
bias. The patient population willing to participate in clinical studies tends to often be
compromised of healthier individuals with the capacity to give consent and travel to the research
facility. For e.g., since for our specific study participants needed to be able to lie flat for one hour
in the MRI scanner, CKD patients with severe pulmonary edema (likely from salt and fluid
overload) could not participate. Also, having age and sex matched healthy controls may have
increased the power of the study (as mentioned above). The controls were chosen with the aim of
expediency given this was a pilot study. Even so, the participant requirements in our study were
relatively not cumbersome, and low risk. As such, we do not suspect a significant selection bias.
Lastly, our study methodology did not include measuring sodium content with previously
used gold standard techniques, and we did not assess tissue water content. Unfortunately, goldstandard sodium measurements tend to be relatively invasive (requiring tissue biopsies) or
exposures to radiation. [4,14-18] Both of these properties often deter subjects from study
participation. Furthermore, since multiple previous studies have validated sodium MRI
measurements against these gold-standards, [4,19,20] we opted to avoid further undue risks
imposed on the study population. On the other hand, we also did not assess tissue water content,
since previous studies [21] have demonstrated that sodium accumulation exceeds water
increases. Since in this pilot study, our MRI scan time was already 1 hour long – in the setting of
multiple measurements averaged to increase SNR for sodium measurements, adding sequences
to measure water content would have increased scan time. More robust investigations should be
performed in follow up studies.
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4.2 Future Work
This section focuses on the future work and other areas that need to be further explored to
expand our understanding and knowledge of sodium accumulation in CKD patients.

4.2.1

Cohort Expansion and Clinical Utility
In order to learn more about the effect of kidney function on the sodium deposition in the

tissues, larger studies are needed that include patients with all the different stages of CKD (15D), and with larger population sizes. As mentioned in Section 1.4.2, the methodology of the
study could also be improved by ensuring the control group is completely healthy, or age, sex,
BMI-matched controls to the patient groups. Furthermore, more detailed statistical and image
analysis could help assess for confounding factors and differentiate between osseous and bone
marrow sodium levels. 24hour urine collections can be used to better estimate the residual renal
function in dialysis patients. Future studies could also include patients on home hemodialysis or
those who have received a renal allograft (both populations have yet to be studied). Since CKD
is a big umbrella term for several different pathophysiological mechanisms of injury in the
kidney, the effect of the etiology of CKD, and its unique pattern of injury, on sodium
accumulation should also be explored. Similarly, acute kidney injury can also result in severe
impairment – sometimes requiring renal replacement therapy. This type of injury has also been
shown to result in sodium accumulation and needs to be studied further. [3] In addition, the
ability of our current treatments (medical or dialysis) to affect the different tissue sodium
reservoirs also will need to be studied further. Lastly, the clinical relevance of sodium
accumulation will need to be explored in future studies (including causes and consequences).
All this information could be utilized clinically to direct CKD patient treatments and provide
information on their prognosis. For e.g., dialysis treatments can be individualized to patients’
sodium accumulation patters – by better understanding a patient’s intrinsic pattern of sodium
accumulation and how dialysis alters this pattern.

4.2.2

Mechanistic Work
As mentioned above, clinical observational studies cannot prove causality, limiting their

scientific potential. Thus, further studies are required - using animal models to determine the
86

direct effect of kidney function (and the different dialysis modalities) on sodium accumulation in
the tissues. Furthermore, while some studies have already explored the mechanisms governing
this sodium accumulation (Section 1.5), more information is needed to assess if these
mechanisms are altered by the uremic toxin-rich environment present in CKD (especially in
severe stages). These studies will need to cover a broad spectrum: from cellular-level studies
assessing the effect of cellular signaling pathways, to clinical studies looking at the effect of
dialysis modalities on tissue sodium fluctuations.

4.2.3

Technological Advancement
In addition, sodium MRI technology is still relatively limited. Due to its low signal-to-

noise ratio, large period of scan time is dedicated to obtain limited information on a sample of
the anatomy (in this study, a single axial slice of the lower leg). Further advancement in this
imaging technology is required to increase SNR and decrease scan time, so that 3-dimensional
anatomical images can be obtained. Such advancement could include using a stronger external
magnetic field (for e.g. 7T MRI), and improving the sequences to shorten acquisition time.
As mentioned in Section 2.4.6, it is incorrect to assume homogeneity of sodium
accumulation in all areas of the skin, likely from the role of the micro-environment in regulating
sodium storage. As such, more complete images may help identify specific patterns of sodium
storage across different tissues, which may be further associated with both healthy and diseased
states. Ideally, 23Na-MRI will become an additional imaging tool in routine clinical use (as
opposed to just research settings), to help improve diagnosis and treatment of patients.
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4.3 Conclusions
This thesis was a pilot observational study measuring non-osmotic sodium storage in
tissues of CKD patients (stages 4-5, HD and PD) compared to controls with normal kidney
function, using non-invasive 23Na MRI technology. We observed that dialysis patients had
significantly higher 23Na level in all tissues studied: skin, muscle and bone, compared to
controls. No statistically significant difference was noted between the three different patient
groups (CKD, HD and PD), despite different levels or residual renal function. Even CKD
participants had evidence of sodium accumulation - albeit not always statistically significant.
Yet, there was a trend of lower sodium levels in CKD participants compared to dialysis ones.
Sodium levels were also correlated with different markers of CKD and other factors
previously known to be associated with higher non-osmotic sodium storage. Soleus and tibia
sodium levels were strongly associated with markers of mineral bone disease and inflammation,
while the effect of age and sex was relatively limited. Even so, significant inter and intra-tissue
heterogeneity was observed, and associated factors appeared to be tissue specific. This finding
points toward an adaptable non-osmotic sodium compartment that can be influenced by local and
global factors.
This study is the first to look at patients on peritoneal dialysis and severe CKD (stages 45), in addition to HD patients. Furthermore, it used 23Na MRI to assess multiple tissues,
including the osseous compartment, which has not been previously reported. Our findings add to
our current understanding of non-osmotic sodium, particularly in the relatively sodium-abundant
CKD states, while also generating hypothesis for future studies.
Non-osmotic sodium measured non-invasively with MRI technology has a lot of potential
for diagnostic, therapeutic and prognostic applications. Yet, more studies are needed for
technological advancement and to better understand sodium metabolism and storage, its causes
and effects, before this potential can be harvested.
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